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Abstract 
 
The large bone defects caused by trauma are generally considered complex and usually 
resulted in delayed union or non-unions, which presents a number of complications for 
orthopedic surgeons. A better understanding of the physiological and biochemical processes 
that occurs in bone defect repair could facilitate development of treatment strategies to 
accelerate the healing of recalcitrant fractures. The emphasis of this thesis is to explore the 
initial early phase of bone healing –an area of research that is gathering considerable interest. 
 
The main purpose of this study is to identify structural differences in bone healing 
hematomas sourced from normal healing bone defects and delayed healing bone defects and 
to assess whether the deliberate alteration of the hematoma structure can enhance the healing 
process of large bone defects. Two different animal models were established using 1-mm 
(normal healing) or 3-mm (delayed bone defects) in diameter, both 2-mm deep, in the rat 
femur. Hematomas were harvested at days 1, 4, and 7 and characterized by scanning 
electronic microscopy (SEM) and the bone healing process validated by means of histology 
and micro-CT. Results showed that clots harvested from the 3-mm defects consisted of 
thinner and tighter fiber structure when compared to the hematomas harvested from normal-
healing defects. It was also found that the inflammatory cytokine levels in the hematomas, 
especially IL-1β, were significantly higher in the delayed healing defects. 
 
In an effort to unravel the role of IL-1β in bone defect sites during thrombogenesis, a series of 
in vitro experiments were conducted on the effect of IL-1β on fibrin polymerization using 
turbidity measurements, SEM, confocal microscopy (CM), and compaction assays. In the 
presence of IL-1β at 500 pg/mL, artificial fibrin clots had shorter lag times, lower Vmax values, 
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and higher maximal turbidity. These results were an indication that clots formed under the 
influence of IL-1 had thinner fibers, thereby yielding a less porous fibrin clot conformation. 
This hypothesis was further supported by the observations made with SEM and CM. In 
addition, the compaction study data showed that clot rigidity was significantly higher in the 
IL-1β treatment group. Finally, we demonstrated that IL-1β most likely had a direct 
interaction with fibrinogen rather than interfering with thrombin enzyme activity, which was 
demonstrated by a fibrinopeptide release assay. This series of experiments suggested that 
changes to fibrin clot structures could be attributed to higher concentration of the pro-
inflammatory cytokine IL-1β. 
 
Finally, we tested whether manipulating the fibrin structure using the anti-coagulation agent 
s-nitrosoglutathione (GSNO) could accelerate and enhance bone healing. Blood kinetics 
modulated by different concentrations of GSNO were assessed using thromboelastography 
(TEG), and this revealed a significantly increased reaction time (R time) and coagulation time 
(K time) with reduced alpha angle and maximal amplitude (MA) at final concentrations of 1 
mM of GSNO. SEM showed that hematomas, formed within large bone defects treated with 1 
mM GSNO, were characterized by thicker fibers and had a more porous fibrin structure, 
whereas quantitative micro CT evaluations confirmed that GSNO treatment resulted in 
significantly increased amount of mineralized bone tissues within large bone defects 
compared with those of control groups, at 7 and 28 days post-treatment. 
 
As an extension to this study, experiments were conducted to verify the impact of IL-1β on 
platelet poor plasma (PPP) clot construction and human blood plasma. Consistent with our 
previous findings, we observed reduced lag time and maximal turbidity in the 500 pg/mL IL-
1β treatment groups compared to the controls. SEM and CM analyses of the PPP clots 
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showed a tight fibrin meshwork associated with the high concentration of IL-1β, which was 
in line with results from human blood plasma. Fibrin clots forming a tightly meshed array of 
thin fibers by addition of IL-1β (500 pg/mL) were found to be associated with resistance to 
fibrinolysis. 
 
In summary, the findings from this project unequivocally showed that the hematoma 
morphology was significantly altered in large bone defects with delayed healing. These fibrin 
differences (thickness and density) were partly attributed to the high concentration of 
proinflammatory cytokines such as IL-1β. It was also found that improvement of the 
structural and biological properties of in-situ blood clots using biologics such as GSNO could 
enhance the de novo healing of large bone defects. This project represents a novel approach 
that has the potential to improve treatments options for large bone defects. 
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Chapter 1: Introduction 
1.1 Background 
1.1.1 The repair of large segmental bone defect is challenging 
Large bone defects, characterized as delayed union (healing) or non-union (non-healing), respectively 
account for 2.5 % and 10 % of all bone fracture cases (Ebraheim et al., 2013; Robinson et al., 2004). 
For patients such cases lead to pain and suffering above and beyond that associated with “normal” 
fractures and also leads to an extended period of immobility. From the perspective of clinical 
management the treatments of large bone defects are a critical issue for orthopaedic surgeons (Gomez-
Barrena et al., 2015). This is especially true for bony non-unions caused by critical-size defects (CSD), 
which has been defined as a bone fragment loss that exceeds the natural capacity of bone to heal 
spontaneously (Schmitz et al., 1986). Restoration of such injuries is often done using autologous 
cancellous bone grafting – considered the ‘gold standard’ for restoring large bone defects (Khan et al., 
2005). However, autologous bone graft materials are not always available and harvesting of bone, 
typically from the iliac crest of the patient, often leads to additional pain and donor site morbidity 
(Goulet et al., 1997; Mertens et al., 2014). 
In the physiological processes of bone repair, there are three consecutive but overlapping stages: 
reactive phase including hematoma (blood clot) formation and inflammation reaction, reparative phase 
including soft and hard callus formation, and bone remodelling phase (Malhotra et al., 2013; Mohamad 
et al., 2012) (Figure 1-1). Successful bone healing is associated with a number of events, including 
adequacy of bone marrow stem cells (BMSCs) and biological growth factors, sufficient blood supply, 
suitable biomaterials, and stability of injured sites (Callum et al., 2012). In clinical practice, various 
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treatment approaches have been developed to aid in the therapy of large bone defects, such as bone-
substitute biomaterials and transplantation of stem cells. However, these approaches have shown only 
marginal improvement in outcomes. Inadequate bone formation, poor mechanical and handling 
properties, a lack of biocompatibility, unpredictable resorbability, and inflammatory reactions remain 
major limitations of the use of bone biomaterials (Pok et al., 2013; Wang et al., 2013). Stem cell 
therapies using mesenchymal derived cells remains a concept at best and clinical uses are still far from 
being realised. 
 
Figure 1-1: The physiological phase of bone healing. 
In the reactive phase, endothelial cells will infiltrate into the hematoma, leading to granulation tissue formation. Afterwards, 
mesenchymal stem cells will differentiate into soft callus and hard callus via endochondral ossification and bony 
substitution, respectively. Eventually, callus will be replaced with lamellar bone by the synergistic effect of osteoblasts and 
osteoclasts within months or years. The figure is adapted from http://www.mc3cb.com. 
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To minimize the side-effects associated with biomaterials, platelet-rich plasma (PRP), a category of 
autologous blood product, has been implemented in recent years across a range of applications, 
including the treatment of musculo-skeletal injuries (Iqbal et al., 2011; Kurikchy et al., 2013). 
Theoretically, the local injection of PRP at the fracture site can interact with thrombin, a central 
mediator of homeostasis which could bring about the formation of a fibrin clot containing a great deal 
of growth factors, providing a fibrin matrix for cellular migration and adhesion. Its effectiveness has 
been confirmed in small bone defect by using PRP to treat patients with mandibular degree II furcation 
defects (Bajaj et al., 2013). There are, however, no studies that unambiguously show that PRPs actually 
improve or accelerate bone healing in animal-based trials, such as rat cranial defect model (Plachokova 
et al., 2007), sheep mandibular defect model (Forriol et al., 2009), and sheep femoral osteotomy 
models (Hernandez-Fernandez et al., 2013). The quality of the hematoma itself may be the common 
factor; in other words, hematomas may be divided into the category of “optimal” and “suboptimal” in 
relation to bone healing (Wolberg, 2007). 
The underlying reason for what makes the hematoma “optimal” or “suboptimal” remains unclear. 
Hematoma quality appears to be associated with the location of where it was formed. Conspicuously, 
scalp hematoma or subcutaneous hematoma in soft tissues cannot develop into new bone tissues, while 
bone fracture hematoma will organize and mineralize into fresh bone tissues (Phillips, 2005). Usually a 
fracture hematoma is formed at a fracture site without complications, but occasionally delayed unions 
or non-unions can still occur (Griffin et al., 2011; Lee et al., 2012). Therefore, there is a knowledge gap 
on hematoma properties at normal-healing, delayed, and non-healing fracture sites. Another interesting 
finding is that transplantation of four-day hematomas from rat femur fracture sites into intramuscular 
sites could generate fresh bone, while the transplantation of two-day hematomas from the same 
position into intramuscular site failed to generate new bone (Mizuno et al., 1990). This strongly 
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indicates that the differences of maturity levels of the inherent structure in hematomas are able to 
considerably influence the capability of bone formation. 
 
There are some defined characteristics of an “optimal” fracture hematoma. First and foremost, an 
optimum quality hematoma must provide a temporary fibrin scaffold that facilitates migration, 
attachment, and differentiation of osteogenic cells (Han et al., 2011; Rajangam et al., 2013), since both 
the migration of osteogenic cells to the fracture sites and the initiation of cell adhesion process could be 
largely attributed to fibrin involvement (Echeverri et al., 2015). More importantly, an optimal 
hematoma is composed of loosely-woven fibrin fibers that better facilitates the migration of BMSCs, 
diffusion of oxygen and nutrients, and removal of metabolic waste (Willie et al., 2010). Thirdly, a 
porous hematoma, due to its high permeability and low density of fibrin fibers, can be more susceptible 
to fibrinolysis, which is more favourable for bone tissue regeneration (Varin et al., 2013). Finally, an 
optimal hematoma must provide a relatively larger total surface area for growth factors adhesion (Oh et 
al., 2012; Woo et al., 2003), which can sustain their slow release rates in the reactive phase (Borrelli et 
al., 2012), thus contribute to a higher rate of differentiation of osteoblasts (Badami et al., 2006; 
Koepsell et al., 2011). For example, the burst release of bone morphogenetic protein-2 (BMP-2) can 
lead to the unintended side-effect of bone absorption as a result of increased recruitment and activation 
of osteoclasts (Lin et al., 2015). In contrast, the slow delivery of BMP-2 has been shown to enhance 
bone formation efficacies in miniature pigs. Therefore, the controlled release of growth factors from the 
hematoma site has a major impact on bone development (Hunziker et al., 2012). 
 
1.1.2 Hemostasis and inflammation 
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Blood circulates in a liquid phase in the cardiovascular system until the occurrence of a vascular injury 
at a bone fracture site, where the contraction of the blood vessels prevents further blood loss, followed 
by the activation of the coagulation cascade that leads to the formation of a hematoma situated between 
the broken fragments (Arwert et al., 2012; Schindeler et al., 2008). In the clotting process there are two 
main pathways: intrinsic and extrinsic (Figure 1-2) (Lazzaro et al., 2012; Wannhoff et al., 2013). The 
schematic diagram illustrates that the common pathway of coagulation cascade is the conversion of 
coagulation factor X into Xa. Thrombin is the final protease in the coagulation cascade and belongs to a 
typical serine protease of chymotrypsin family (Rawlings et al., 2010) and is engaged in both pro- and 
anti-coagulant functions (Huntington, 2012). At the fracture sites, thrombin exploits its potent pro-
coagulant function to stimulate clotting factor X activation via a positive feedback loop, thereby further 
cleaving fibrinogen into fibrin monomers in a timely fashion. Ultimately, these fibrin monomers will 
polymerize to form a mature web-like fibrin clot with the assistance of coagulation factor XIII 
(Chernysh et al., 2012; Elliott et al., 2013). 
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Figure 1-2: The intrinsic and extrinsic pathways of coagulation cascade. 
The intrinsic pathway begins with the activation of prekallikrein, high molecular weight kininogen (HMWK), and 
coagulation factor XII (FXII). This pathway has been recognized as a linear cascade of zymogen activation steps, which 
causes the formation of intrinsic tenase complex (FIX-FVIIIa). On the other hand, the extrinsic pathway starts with tissue 
factor (TF) originated from trauma. TF can activate factor VII (FVII) into FVIIa to form extrinsic tenase complex (TF-
FVIIa). Both complexs have the common pathway in which factor X converts into Xa. FXa can further active factor V, 
generating the prothrombinase complex (FXa-FVa), promoting the conversion of prothrombin to thrombin. Thrombin can 
catalyse fibrinogen to produce fibrin (adapted from ref [Lazzaro]).  
 
Fracture hematoma formation occurs within a few minutes following a bone injury via the extrinsic 
pathway. During hematoma formation, this clotting process is a cascade of biological events that 
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engage not only activated coagulation factors in the hematological system, but also a subset of other 
factors derived from activated platelets, periosteum, bone marrow, and surrounding soft tissues such as 
osteogenic, angiogenic, and growth factors, and also inflammatory cytokines (Kolar et al., 2010). In 
particular, the active participation of platelets is considered as a core constituent of hemostasis that 
prompts thrombogenesis through a number of mechanisms. With platelet stimulation, numerous pro-
inflammatory cytokines, such as interleukin-6 (IL-6), IL-8, and tumour necrosis factor alpha (TNF-α), 
are released from the stored granules, recruiting other inflammatory cells into the hematoma thus 
initiating the repair cascade (Ai-Aql et al., 2008). Interestingly, platelet-derived IL-1β expression is 
believed to produce pre-messenger RNA (mRNA) in activated platelets and recognized to be a potent 
inducer of acute phase response (Morrell et al., 2014). In addition, the binding of fibrinogen to platelet 
glycoprotein IIb/IIIa receptors (GP IIb/IIIa) plays a crucial role in supporting accumulation of 
neighbouring platelets, leading to the formation of a hemostatic platelet plug (Sivaraman et al., 2011) 
(Figure 1-3). 
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Figure 1-3: Platelet activation following bone injury. 
PDGF, platelet-derived growth factor; TGF-β, transforming growth factor; EGF, epidermal growth factor; VEGF, vascular 
endothelial growth factor; SDF, stromal cell–derived factor; vWF, von Willebrand factor; ADP, adenosine 5’-diphosphate. 
 
The structural framework of hematomas spaning the whole fracture gap acts as an initial fibrin template, 
whereby neovascularization and mesenchymal progenitor cells migrate inwards from the fracture 
boundaries under the chemotactic effects of pro-inflammatory cytokines trapped within the ﬁbrin 
network (Claes et al., 2012). Polymorphonuclear neutrophils (PMNs) have been shown as the cells that 
are first recruited (less than 1 hour) into fracture hematomas (Chung et al., 2006). Growing evidence 
indicates that short-lived PMNs (around 1 day) acts as the source of IL-6 and may have a deleterious 
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effect on fracture repair (Bastian et al., 2011; Gokturk et al., 1995). Subsequently, inflammatory 
macrophages, immune cells, BMSCs, and endothelial cells are chemotactically recruited by biological 
cues of proinflammatory cytokines, which is vital to successful bone healing (Hollinger et al., 2008). 
Although previous data suggests that persistent inflammation is detrimental to bone regeneration, 
recent studies have revealed that a certain degree of inflammation is necessary for early fracture 
healing (Mountziaris et al., 2008). Evidence for this is a study that showed a remarkable impairment of 
fracture healing when anti-inflammatory drugs were applied (Dimmen et al., 2009; Konstantinidis et al., 
2013).  
 
1.2 Research Aim 
The hypothesis tested in this thesis is that differences in hematoma structures determine the speed with 
which a bone defect will heal. In this scenario, a hematoma with thin and densely pack fibers is 
associated with delayed bone healing defects, whereas in normal healing defects the clots consist of 
thicker and more loosely arranged fibers. We therefore propose that the hematoma structure can be 
deliberately modified using biological agents in order to augment bone defects sites. 
The research questions to be addressed in this thesis are: 
1. Identify the structural and biological differences in hematomas between normal and delayed bone 
healing using rat femoral hole-drilling model. 
2. Investigate whether there is a direct link between proinflammatory cytokines and fibrin structure in 
rat platelet-poor plasma  and human whole blood in vitro. 
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3. Examine whether altering the structural property of fibrin fibers within in situ blood clots with 
biological agents, such as GSNO, could accelerate delayed bone healing in vivo. 
 
1.3 Thesis outline  
 
 
Figure 1-4: Conceptual framework of this thesis. 
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This thesis is presented in a publication style. Thus, chapters 2–5 are stand-alone publication 
manuscript. 
Chapter 1 is the introduction, which includes the research background, aim, and outline.  
 
Chapter 2 is a systematic review of current status and future clinical implications of fracture 
hematomas.  This review provides a detailed outline of the theoretical knowledge on how fibrinogen is 
converted to fibrin fibers under the influence of thrombin. This provides an explicit understanding of 
the inherent structural properties of hematomas within normal bone healing defects, which can provide 
a guideline for custom made hematomas that could act as natural scaffolds to aid in facilitating cell 
migration and osteogenic differentiation at bone injury sites. 
 
Chapter 3 describes the characterization of early bone defect hematomas using scanning electronic 
microscopy (SEM) between normal bone healing and delayed bone healing, including fiber diameter 
and fiber density. The results demonstrated that the quality of hematomas is significantly altered in a 
delayed bone healing defect compared to a normal healing defect. The clots from the healing defects 
were more porous with thicker fibrin fibers compared to those in the delayed healing defects, whose 
fibers were thinner and more densely packed. These differences appear to be caused by increased levels 
of inflammatory cytokines, particularly IL-1β, in the delayed healing defect. In order to confirm the 
underlying connection, the direct effect of IL-1β on fibrin clot structure in purified fibrinogen solutions 
has been tested via a series of in vitro assays. To further investigate whether manipulation of blood clot 
structure could influence the bone healing, s-nitrosoglutathione (GSNO) was used to modulate an in 
situ hematoma to accelerate healing of large bone defects. 
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Chapter 4 describes an investigation into the effects of IL-1β on fibrin clot architecture in platelet-poor 
plasma solutions, which allows for the visual monitoring of fiber changes under low magnification 
microscopy. The experimental data indicate that IL-1β has a significant impact on reduction in fiber 
diameter and increase in fiber density, which is in line with purified fibrinogen studies. This evidence 
may shed new light on an innovative solution (manipulation of hematoma) that has the potential to 
speed up healing of large bone defects.  
 
Chapter 5 further explores the influences of IL-1β on clot construction in human whole blood, which 
more closely mimics the in vivo environment. The outcomes are consistent with previous investigations 
of PPP clots, suggesting that IL-1β can positively participate in thrombogenesis thus altering clot 
morphology, biomechanical strength, and thrombolytic activity. The molecular mechanism of IL-1β in 
hemostasis and hematoma formation still needs to be determined, but optimizing the healing process of 
large bone defects, possible by targeting IL-1β interaction sites on fibrinogen, may have potential 
therapeutic implications. 
 
Chapter 6 discusses how to modulate the fibrin structure in purified fibrinogen / platelet-poor plasma / 
whole blood in response to the presence of IL-1β. The most critical aspect of this study is to be able to 
produce fibrin clots with thicker fibers in a loose conformation since this promotes faster cell migration 
and increases cell alignments along the length of the fibers. The main purpose of this study was to 
investigate the blood clot properties in the bone healing and potentially develop a novel therapeutic 
approach that can significantly reduce the costs and clinical complications associated with large bone 
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defects. Such a concept could potentially revolutionize the treatment of such injuries and reduce the 
burden both to the health care system and the patient.  
 
Chapter 7 summarizes the overall research findings. This part recaps the thesis essentials, scientific 
significance, and implications in this study. Finally, future research is proposed.   
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Abstract 
 
Blood clots (hematomas) that form immediately following a bone fracture have been shown to be vital 
for the subsequent healing process. During clotting process, a number of factors can influence the fibrin 
clot structure, such as fibrin polymerization, growth factor binding, cellular infiltration including 
platelet retraction, protein concentrations, and cytokines. The modulation of the fibrin clot structure 
within the fracture site has important clinical implications and could result in the development of 
multifunctional scaffolds that mimic the natural structure of hematoma. Artificial hematoma structures 
such as these can be created from the patient’s own blood and can therefore act as an ideal bone defect 
filling material for potential clinical application to accelerate bone regeneration. 
 
Key words: Large bone defect; fracture hematoma; blood clot; fibrin clot; structural properties 
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2.1 Introduction 
Large segmental bone loss, especially if caused by traumatic injuries resulting in severe bone and soft 
tissue destruction and major blood loss, often leads to delayed healing or non-unions. This results not 
only in high degree of pain and suffering for the patient but also poses a major burden on the healthcare 
system since individual cases tend to extend over a number of years (Gomez-Barrena et al., 2015; 
Mehta et al., 2012). Even when disregarding the additional complications, bone defects beyond a 
certain size threshold have no intrinsic ability to heal, rendering the management of large segmental 
bone defects the most challenging patient cohort facing orthopedic surgeons (Pollak et al., 2008). From 
a clinical perspective it is important to understand the intricate biological processes involved during 
bone healing to achieve the best outcomes for the patients.  
The bone healing process goes through three consecutive and overlapping stages: hematoma formation, 
callus formation, and bone remodelling (Claes et al., 2012). Blood vessels at the fracture site contract to 
prevent sustained blood loss and is immediately followed by a coagulation cascade that leads to the 
formation of a hematoma situated between the broken fragments (Schindeler et al., 2008). Hematoma 
formation occurs within minutes of a fracture injury and includes a cascade of biological events that 
includes activated coagulation factors of the hematological system, as well as a number of molecular 
factors derived from the periosteum, bone marrow, and surrounding soft tissues, such as pro-
inflammatory cytokines, growth factors as well as osteogenic and angiogenic factors (Marsell et al., 
2011). In essence, this hematoma is a definitive hemostatic fibrin clot network characterized by 
activating platelets that connect with fibrin fibers and entraps many components such as erythrocytes 
and leukocytes (Lam et al., 2011; Laurens et al., 2006). In spite of fracture hematomas having such a 
pivotal role in initiating the bone healing process (Kolar et al., 2011; Kolar et al., 2010) there is a 
surprising paucity of scientific literature that describes the intrinsic structural properties of a blood clot. 
Chapter 2: Review Paper 
 
                                                                                 
42 
Given the physiological role of the fracture hematoma it is important to characterize intrinsic structural 
properties of blood clots formed at a fracture site in order to develop treatment strategies that can 
accelerate bone regeneration and repair.  
 
2.2 Current concepts for management of non-union and large bone defects 
It has been estimated that delayed union or nonunions account for approximate 5–10% of all long bone 
fractures (Blick et al., 1989; Fernandez-Palazzi, 1969; Jones, 1965). Traditionally, nonunions can be 
divided into two primary categories: atrophic (avascular) and hypertrophic nonunion (Paley et al., 
1989). The avascular type of nonunion most often results from inadequate blood supply at the fracture 
site, whereas hypertrophic nonunions are typically attributed to mechanical instability at the fracture 
site (Panagiotis, 2005). There are major benefits to be gained, for both individual patients and the 
health sector, from improving to therapeutic strategies used to deal with bone nonunions that addresses 
the mechanical and/or biological environments (Jones et al., 1955; Simon et al., 1984; Simpson et al., 
2006; Simpson et al., 1990; Souter, 1969). Although some simple treatment options, such as, growth 
factors or cell-based approaches, have successfully been applied to manage small bone defects, it may 
be that osteoconductive scaffolds offer the best structural environment for healing of large segmental 
bone defects (Balogh et al., 2012). 
At present, autografting is still regarded as the gold standard when dealing with large segmental bone 
defects (Khan et al., 2005). The supply of autografts is limited to the iliac crest of the patient’s hip or 
alternatively the fibulas (Mertens et al., 2014) but this is associated with an additional surgical 
interventions and donor site morbidity (Goulet et al., 1997). By contrast, allograft bone has been used 
as a substitute and is available in greater quantities since it is harvested from cadavers; however, the 
threat of infections, transmission of diseases, and immunological rejections are major limitations to its 
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use (Khan, et al., 2005; Mankin et al., 2005). Studies have also revealed a higher rate of micro-fractures 
associated with allograft bone when loaded, resulting in a 5-year failure rate of 30% or higher 
(Enneking et al., 2001; Wheeler et al., 2001). In light of the limitations of both autograft and allograft 
bone, bone substitute materials have also been trailed to aid bone healing of segmental sized defects; 
however, in spite of large research efforts in this field these approaches have so far only yielded minor 
improvements in therapeutic efficacies. A lack of biocompatibility, insufficient mechanical strengths, 
rapid absorbability, inflammatory reactions, and unsatisfactory de novo bone formation are the major 
concerns regarding such materials (McKee, 2006). The treatment strategies of nonunions continue to be 
a challenging problem for orthopedic surgeons. 
 
2.3 The influence of hematoma on bone formation 
In the event of a bone fracture injury, the hematoma acts as a ‘natural scaffold’, which forms when the 
extrinsic coagulation pathway is activated. This pathway depends on a complex interaction between 
three main components—coagulation factors (mostly proteolytic enzymes), activated platelets, and 
blood cells (Einhorn et al., 2015). Under normal physiological conditions, tissue factors (TF) are 
released that bind plasma factor VII, thus initiating the extrinsic clotting cascade (Figure 2-1) (Lazzaro 
et al., 2012). During the clotting process, activated platelets can alter the hematoma structure by clot 
retraction (Feghhi et al., 2011), whereas the release of polyphosphates increase the pore size and reduce 
the number of fiber branching points (Mutch et al., 2010); thrombospondin, on the other hand, 
promotes formation of thinner and denser fibers (Nehls et al., 1996). Other cells, such as leukocytes, 
fibroblasts, and endothelial cells impacts the fibrin structure by secreting tissue factor that modulate 
thrombin production (Campbell et al., 2008; Campbell et al., 2009; Ovanesov et al., 2005) and 
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erythrocytes can increase the rate of lateral aggregation in fibrin polymerization by expressing 
nitrosated analogue, GSNO (Geer et al., 2008). 
 
Figure 2-1: The extrinsic pathways of coagulation cascade in fracture hematoma formation. 
This extrinsic pathway starts with tissue factor (TF) originated from trauma. TF can activate factor VII (FVII) into FVIIa to 
form extrinsic tenase complex (TF-FVIIa). This complex converges into the common pathway in which factor X converts 
into Xa at the assistance of Ca2+ and a phospholipid (PL). FXa will further active factor V, generating the prothrombinase 
complex (FXa-FVa), promoting the conversion of prothrombin to thrombin. Finally, thrombin catalyzes fibrinogen to 
produce fibrin, resulting in a fibrin clot formation that achieves homeostasis. 
 
Studies show that removing an organized hematoma at the fracture site at 2 and 4 days post-fracture, 
will dramatically affect the capability of normal bone healing in rat femoral fracture model (Grundnes 
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et al., 1993). In a study using open middle tibial osteotomies in rabbits, a similar delay in bone healing 
has been observed with repeated irrigation and debridement of a fracture site, which rinses away the 
fracture hematoma (Park et al., 2002). Furthermore, in a sheep tibial osteotomy model, when fracture 
hematomas were removed at 4 and 7 days the result was a significant delay of early fracture healing 
(Peters et al., 2012). These findings are clear indications that a stable hematoma is crucial for the initial 
bone healing (GÜNAY et al., 2013; Van der Ende et al., 2013). 
The majority of fracture-related research emphasizes the importance of hematoma during the early 
stages of the healing process. However, it is also the case that hematomas that persist without normal 
fibrinolysis become obstacles that impedes normal cellular trafficking, thereby interfering with 
angiogenesis and ossification within the fracture zone (Yuasa et al., 2015). Plasminogen activator 
inhibitor-1 is a key enzyme of fibrinolytic system that inhibits plasminogen activation and which limits 
the amount of plasminogen that can be converted to plasmin available to dissolve the fibrin network 
(Sprengers et al., 1987). Plasminogen knockout mice have a plasmin deficiency that negatively 
interferes with normal bone repair and indicates that fibrin degradation is essential for bone metabolism 
(Mao et al., 2014).  Similar studies in mice have shown that the absence of fibrinolytic protease genes, 
such as plasminogen, urokinase-type plasminogen activator (uPA), and tissue-type plasminogen 
activator (tPA), substantially reduces bone turnover at the damaged sites by interfering with 
macrophage accumulation (Kawao et al., 2015). It has been proposed that plasminogen/plasmin have a 
direct effect on osteoblast and osteoclast functions and participates in the process of bone tissue 
reorganization in a knockout mouse model (Kanno et al., 2011). These finding therefore support the 
notion that manipulation of fibrinolysis-related genes may have therapeutic uses that could enhance 
fracture healing (O'Keefe, 2015). 
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2.4 The influence of hematoma on growth factors 
Following a fracture, a cross-linked fibrin meshwork is formed by platelet clump and initiation of 
clotting cascade with generation of thrombin stimulating cleavage of fibrinogen to fibrin. Consequently, 
a cohort of cytokines and growth factors, such as, vascular endothelial growth factor (VEGF), 
transforming growth factor-beta 1 (TGF-β1), and bone morphogenetic protein (BMPs), are released 
from platelet degranulation and periosteum, which are trapped by the developing hematoma (Binder et 
al., 2015; Borges et al., 2013). Besides releasing osteogenic factors, the periosteum has also been 
shown to have a vital role in the maturation of fracture hematomas by mediating chondrogenesis and 
enchondral ossification (Ozaki et al., 2000). The binding of growth factors to fibrinogen (fibrin) or 
extracellular matrix (ECM) proteins are responsible for inducing early bone healing (Hulsart-Billstrom 
et al., 2015; Martino et al., 2013). Indeed, by acting as a provisional “reservoir”, a well-organized fibrin 
clot not only prevents the burst release of growth factors but also provides space for supporting cell 
infiltration, proliferation, and differentiation which together speeds up the bone healing process 
(Mosesson, 2005). A tight clot conformation with thinner fibers would tend to retain relatively lager 
amounts of growth factors (Oh et al., 2012; Woo et al., 2003), but also tend to retard cellular ingress. 
By contrast, a loose clot conformation with thicker fibers will as result of higher porosity be more 
susceptible to fibrinolysis, which is advantageous for bone tissue restoration (Varin et al., 2013). 
 
2.5 Variables that relate to structural properties of blood clots 
The structural parameters of fibrin clots are relevant in fields such as cardiology and hematology and 
are characterized by fiber diameter, density, the number and property of branch points, distances 
between branch points, and dimension of the pores (Hellerer et al., 1980). Factors, such as, 
microgravity (Farahani et al., 2008; Nunes et al., 1995), local PH value (Mosesson et al., 1987), 
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temperature (Wolberg et al., 2008), ionic strength (Nair et al., 1986), and concentrations of chloride 
and calcium ions (Carr et al., 1986; Carr et al., 1990), can affect ﬁbrin polymerization and ultimately 
the properties of clots. Above all, the concentrations of clotting factor proteins, such as fibrinogen and 
thrombin, have a considerable effect on clot conformation. For example, low concentration of thrombin 
(or fibrinogen) generates turbid, thick, and loosely-woven fibrin fibers which results in highly 
permeable fibrin clots, whereas a high concentration of thrombin (or fibrinogen) results in a less 
permeable clot characterized by non-turbid thin and tightly-packed fibrin strands and a less permeable 
clot (Figure 2-2A)  (Campbell, et al., 2009; Rahmany et al., 2013). These vastly different clot 
structures result in completely different fibrinolytic properties in that clots formed with low 
concentrations of thrombin are more susceptible to fibrinolysis, which are more prone to premature 
lysis and bleeding. On the other hand, clots formed with high concentrations of thrombin are often 
resistant to fibrinolysis and often implicated in thrombosis (Mosnier et al., 1998; Varin, et al., 2013). 
Besides effecting the rate of fibrinolysis, thick fibers often exhibit a granular structure, whereas thin 
fibers, when observed by atomic force microscopy (AFM), show a corrugated surface, which suggests 
that the thinner fibers have a rougher surface topography than does thicker fibers (Figure 2-2B) 
(Yermolenko et al., 2011). Importantly, surface roughness is considered a determinant of cellular 
attachment thereby influencing bone healing (Albrektsson et al., 2001; Davies, 1996). 
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Figure 2-2: The morphology of fibrin fibers formed by different concentrations of thrombin. 
In panel A, fibrin clots generated by the mixture of pure fibrinogen (1 mg/mL), thrombin (0.5 or 5 U/mL), and CaCl2 (10 
mM) were observed using scanning electron microscopy (SEM) (① -② ) and confocal microscopy (CM) (③ -④ ), 
respectively. In addition, blood clots formed by the addition of thrombin (0.5 or 5 U/mL) were detected under SEM (⑤-⑥). 
E represents erythrocytes and PL indicates platelets. Scale bar is 20 µm for SEM and 10 µm for CM. In panel B, the 
topography and toughness of thick (diameter > 400 nm) and thin fibers (diameter ≈ 200 nm) were assessed using AFM (⑦
-⑧). Red colour corresponds to high, blue to low topographic features.  
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2.6 Fibrin fiber formation and its potential influence on fracture healing 
2.6.1 Fibrinogen structure and fibrinopeptide release 
Individual fibrinogen molecules are approximately 45 nm long and 5 nm wide and composed of 6 
paired polypeptide chains (AαBβγ)2 connected together with 29 disulfide bridges (Wolberg, 2007). It 
consists of the central nodule (E domain), β- and γ-nodules (D domain; red dashed circles), Coiled-coil, 
and αC regions (Figure 2-3A) (Medved et al., 1983). More specifically, the central part of this 
molecule–the N-terminal disulfide knot (NDSK) fragment–contains fibrinopeptide A (light blue 
circles), fibrinopeptide B (brown circles), and the proximal portions of coiled-coils (Figure 2-3B) 
(Litvinov, Yakovlev, et al., 2007). The initiation of fibrin polymerization is triggered by the thrombin 
cleavage of FpA from the N-termini of Aα chains to generate desA-NDSK, which is followed by 
cleavage of FpB from the N-termini of Bβ chains to yield desAB-NDSK (Litvinov et al., 2005). In 
solution the FpA is typically cleaved off more quickly than FpB, whereas for surface-adsorbed 
fibrinogen the opposite is the case and FpB is cleaved more rapidly than FpA (Adamczyk et al., 2011). 
The possible explanation for this difference is that the accessibility of FpB for thrombin cleavage is 
easier than FpA when the fibrinogen molecules are adsorbed on the surface of solid substrates (Ciesla 
et al., 2013; Riedel et al., 2011). It has been suggested that the deposition of FpB in hematomas in bone 
fracture sites may be responsible for the attraction of polymorphonuclear leukocytes (PMN), 
mesenchymal stem cells (MSC), and fibroblasts (Senior et al., 1986). 
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Figure 2-3: Schematic representation of consecutive phases of fibrin fiber formation. 
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This figure demonstrates the following steps (A): (1) During coagulation cascade, 2 pairs of binding sites (termed A- and B-
knobs) in the E domain are exposed after cleavage of FpA and FpB by thrombin, and a- and b-pockets located in the γ- and 
β-nodules of the D domain are constitutively open, respectively. (2) The double-stranded, half-staggered protofibrils 
formation via knob-pocket interactions in an end-to-end manner. (3) Upon FpB release, lateral aggregation of protofibrils 
enhanced by untethered hemophilic αC-αC interactions, producing αC polymers. (4) The paracrystalline arrangement of 
protofibrils into a fibrin fiber with a periodic cross-striation of 22.5 nm. (5) Two types of branch junctions. This figure 
depicts theoretical computer modelling of bilateral fibrin branch junctions (Left) and equilateral fibrin branch junctions 
(Right). (B) Schematic representation of fibrinogen molecules and thrombin’s cleavage sites. Fibrinogen consists of three 
different polypeptide chains: Aα, Bβ, and γ, which assemble with their N-termini in a central E domain. The C-termini of 
Bβ and γ chains extend to form distal D domains, whereas the C-termini of Aα chains fold back on the coiled-coil and 
interact with the central E domain. The E domain contains N-terminal disulfide knot (NDSK) fragment bearing the 
fibrinopeptide A and B, which can be cleaved by thrombin during the course of fibrin polymerization. After cleavage of 
FpA, NDSK will be converted into desA-NDSK monomer that can be further cleaved FpB to generate desAB-NDSK 
monomer. (C) Schematic representation of αC polymer formation.  This figure displays compositions of monomeric αC 
regions (top) including a flexible αC connector and a compact αC domain that can be divided into N-  and C- terminal 
subdomains (denoted by“ N ” and “ C ”, respectively). Interaction within N- terminal subdomains in different αC regions 
via self-association through β-hairpin swapping, but interactions between the αC-connectors and C- terminal subdomains 
are reinforced by factor XIIIa crosslinking. It has been shown that the identical monomeric αC domains coming from 
opposite directions in different colors, brown, green, blue, and light blue, for clarity. There are a number of donors and 
acceptors distributing in the αC-connectors and C- terminal subdomains, respectively. 
 
2.6.2 Knob-pocket interactions 
The sites of N-terminal α-chain motif Gly-Pro-Arg-Pro (GPRP), known as knob ‘A’, becomes exposed 
upon the release of FpAs (Koo et al., 2012). Knob ‘A’ is complementary to pocket ‘a’ positioned in the 
γ chains of the D domain of another ﬁbrinogen molecule, resulting in A:a interactions (Figure 2-3A). 
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These interactions are quite stable (Everse et al., 1998; Kostelansky et al., 2002) and lead to the 
spontaneous formation of half-staggered, double-stranded, twisting protofibrils (Krakow et al., 1972; 
Muller et al., 1984); A:a interactions are therefore considered the main driver of fibrin polymerization 
initiation (Hellerer, et al., 1980). Subsequently, the new N-terminal β -chain motif Gly-His- Arg-Pro 
(GHRP), namely knob ‘B’, will be exposed after the release of FpBs (Doolittle et al., 2001). Individual 
‘B’ knobs combine with a complementary-binding ‘b’ pocket in the β chains of the D domain of 
neighboring molecules (Lord, 2007; Mosesson et al., 2001). Although there is evidence for the physical 
presence of B:b interactions (Litvinov, Gorkun, et al., 2007), their functional role are still not known. 
Release of FpA usually occurs before FpB and is sufficient to transform fibrinogen into fibrin. 
However, normal polymerization requires calcium to bind at the 2-site in fibrinogen before the 
initiation of B:b interactions and lateral aggregation and fiber thickness depends on a calcium-
dependent conformational changes that occur concomitant with the B:b interaction (Kostelansky et al., 
2004). If FpAs are cleaved by certain snake venoms in the absence of FpBs, the resultant fibrin clots 
are composed of thinner ﬁbers than those formed by cleavage of both ﬁbrinopeptides, indicating that 
B:b interactions are closely related to the lateral aggregation of protoﬁbrils (Holm et al., 1986; Shainoff 
et al., 1979). Dysfibrinogenemia is a condition of structurally abnormal fibrinogens that is due to 
mutations in the coding regions of the A, B, or  gene (Cunningham et al., 2002). Metz and 
Frankfurt XIII cases (named so after the city where the patients were first evaluated) have been shown 
to have ﬁbrinogen molecules that are homodimers, such that FpBs can be cleaved rather than FpAs and 
which leads to clot structures with thinner ﬁbers at low temperature (Galanakis et al., 1993). This 
implies that B:b interactions seems to occur when A:a interactions are compromised. At the fracture 
site, impaired knob-pocket interactions leads to weak and unstable hematoma and have a tendency to 
bleeding (Kononova et al., 2013). 
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2.6.3 Oligomer and protofibril formation 
The release of FpAs by thrombin cleavage exposes knob ‘A’, which  then connects with pocket ‘a’ in 
adjacent molecules which starts the process of assembling oligomers via A:a interactions (Figure 2-
3A). A third monomer molecule can be added into protofibrils in the same end-to-end, half-staggered 
fashion.  The oligomers lengthen to form 4–10 nm wide and ~200 nm long double-stranded protofibrils 
(Walsh et al., 1999). There is a 22.5 nm repeating pattern equivalent to one-half the length of the ﬁbrin 
monomer has been identified as cross-striations of ﬁbers and is visible using transmission electron 
microscopy (Weisel et al., 2001). The D-D interface comprises residues 275–300 of the  nodule and is 
the most easily recognized feature with most crystal conformations (Weisel et al., 1978). This interface 
is relatively weak and is the first to break when any stretching force is applied on the ﬁbrinogen 
oligomers (El-Hakim, 1999). A higher rate of protofibril assembly was mostly associated with a 
number of thinner fiber generations (Geer, et al., 2008), forming a mechanically stable fracture 
hematoma with low fiber density favorable for controlling hemorrhage at the bone defects (Di Stasio et 
al., 1998; Lord, 2011). 
2.6.4 Lateral aggregation 
Protofibrils are intermediate polymers in which the FpA has been removed. Subsequent release of FpB 
from these oligomers allows a lateral aggregations that generate multi-stranded fibers in a side-by-side 
manner (Figure 2-3A) (Doolittle, et al., 2001). Lateral convergence between protoﬁbrils contributes to 
produce thicker ﬁbers on the condition that their lengths reach a certain threshold. A number of 
structural sites have been investigated or postulated to involve in protofibrilar lateral aggregation, such 
as, knob ‘B’ and pocket ‘b’, the C-terminal positions of the γ-nodule and two adjacent β-nodules, 
coiled-coils, and αC regions (Okumura et al., 2006; Yang et al., 2000). Unlike the initial formation of 
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protoﬁbrils, in which there is no discernible turbidity increase during a “lag” period, lateral aggregation 
is capable of inducing a noticeable increase in turbidity defined as the mass/length ratio of the fibrin 
fibers  (Carr et al., 1977; Wolberg, 2007). Recently, Perez pointed out that when both the rate of 
protoﬁbrils formation and lateral aggregation increased, the results were thinner fibers (Perez et al., 
2014). However, the fibrin fibers are thicker if either lateral aggregation or protoﬁbril formation 
increased (Muenster et al., 2013). In most cases, the fibrin molecules have a regular alignment in the 
longitudinal direction and additional new protoﬁbrils are linked to the outside of an existing ﬁber by 
virtue of the 22.5-nm periodical repeats. This may provide a mechanism that limits excessive growth of 
ﬁber thickness, since they stop aggregating laterally when the energy used to stretch a new protoﬁbril 
exceeds the energy required for bonding (Janmey et al., 2009). In the fracture hematoma, thicker fibers 
are thought to be more beneficial for the migration and adhesion of endothelial cells and fibroblasts 
along with the length of fibers, which can accelerate the process of bone healing at a faster rate (Nehls, 
et al., 1996; Shats et al., 1997). 
2.6.5 The αC regions  
The C-terminal portion of each Aα-chain, the αC region (residues Aα221-610), contains a ﬂexible 
segment αC-connector (Aα221-391), and a quite compact αC-domain (Aα392-610) (Figure 2-3A, 2-
3C) (Medved et al., 2009; Tsurupa et al., 2002). The αC-domain is composed of a globular and an 
extended portion, which are juxtaposed to non-covalently tether to E domain of fibrinogen where they 
interact intra-molecularly (Mosesson et al., 1981; Veklich et al., 1993; Weisel et al., 1985). Studies 
with αC-domain fragments found that the αC-domain can be divided into two subdomains, N-terminal 
subdomains (Aα392-503) and C-terminal subdomains (Aα504-610) (Burton et al., 2007; Burton et al., 
2006; Tsurupa et al., 2009). During the conversion of fibrinogen to fibrin, the αC-domains dissociate 
from the E  domain thereby undergoing significant conformational alteration, enabling them to interact 
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inter-molecularly within and between protofibrils, forming αC polymers (Veklich, et al., 1993). 
Specifically, the αC polymer polymerization involves two different processes: self-association within 
N-terminal subdomains via β-hairpin swapping and factor XIIIa-mediated crosslinking between C-
terminal subdomain and the αC-connector (Tsurupa et al., 2012). Clots formed by a recombinant 
fibrinogen Aα251 missing the αC regions are made up of thinner, denser, and more branch points fibers, 
competing with ones formed by the normal fibrinogen (Gorkun et al., 1998). It is generally accepted 
that αC regions play a crucial role in augmentation of lateral aggregation and lack of αC regions will 
lead to impaired fibrin polymerization (Gorkun et al., 1994; Koo et al., 2010). Recently, an in vitro 
study showed that polymerization of the αC polymer substantially affects the activities of endothelial 
cells via the focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK1/2) signaling 
pathways thereby promoting wound healing (Yakovlev et al., 2014). To our best knowledge, there was 
no direct evidence to verify the relation between αC polymer and bone healing. 
2.6.6 Role of factor XIII crosslinking 
Factor XIII is a 325.8 kDa heterotetramer and its structure is made up of two identical globular A 
subunits non-covalently linked to 2 FXIII-B subunits (Ashcroft et al., 2000; Muszbek et al., 1999; 
Schwartz et al., 1973). Activated Factor XIII in the presence of thrombin is able to produce 
intermolecular γ-glutamyl-ϵ-lysyl covalent bonds between the γ406 lysine (Lys) of one γ-chain and the 
γ398/399 glutamine (Gln) of another γ-chain (Chen et al., 1971; Doolittle et al., 1971; Purves et al., 
1987). There are controversies concerning the occurrence of γ-γ crosslinking longitudinally within 
protoﬁbrils or transversely between protoﬁbrils (Mosesson, 2004; Weisel, 2004). The homogenous γ-
glutamyl-ϵ-lysyl bridging also happens among several amine donors and lysine acceptors in α-chains, 
thereby generating larger molecular weight αC polymers as described (See the αC regions) (Folk et al., 
1977; Matsuka et al., 1996; Sobel et al., 1996) . In addition, cross-linking can occur between α- and γ- 
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chains (Shainoff et al., 1991), but this α-γ crosslinking has less impact on the rigidity of clots 
(Standeven et al., 2007). Regardless of the type of cross-linking, the strong covalent bond within and 
between protoﬁbrils renders the fibrin polymerization process irreversible by strengthening the 
mechanical stabilization of ﬁbrin polymers. The speed of crosslinking varies depending on what 
polymers are involved, such that the rate of α-α crosslinking is significantly slower than γ-γ 
crosslinking, a process that may be attributed to the complexity of αC polymer formation involving a 
vast number of donors and acceptors reactions (Guthold et al., 2007). In spite of this, α-α crosslinking 
takes center stage in determining the physical properties of clots, such as stiffness, elasticity, and 
tautness compared to γ-γ crosslinking (Duval et al., 2014; Helms et al., 2012). In clinical a setting the 
local application of factor XIII into bone defects has been proposed in an effort to boost new bone 
formation, but the anticipated outcomes still remain controversial (Claes et al., 1985; El-Hakim, 1999; 
Hellerer, et al., 1980). 
2.6.7 Branch and network formation  
The branching process is accompanied by the elongation and the thickening of ﬁbrin ﬁbers rather than 
an independent event. There are two classifications of branch junctions when forming a 3-dimensional 
clot network (Figure 2-3A) (Mosesson et al., 1993). The first one, known as a “bilateral junction”, 
occurs when a double-stranded protoﬁbril combine laterally with another one, resulting in four-
stranded fibril, which then again diverges into the original two separate protoﬁbrils. The second type of 
fibrin branching, called an “equilateral junction”, happens when three fibrin molecules converge to 
form three double-stranded fibrils. Fibrinopeptide, if released slowly, produces clot networks that are 
likely to have fibrin fibers with equilateral junctions that are less branched and flexible (Mosesson, et 
al., 1987). Generally speaking, the quantity of branch points in a fibrin clot is inversely proportional to 
the size of the ﬁbers (Ryan et al., 1999). Together these observations suggest that, conditions that 
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promote lateral aggregation (i.e. thick fibers) are prone to form clots composed of lager pore size and 
few branch points, whereas conditions that impede lateral aggregation (i.e. thin fibers) tend to produce 
clots with smaller pore size and more branch points. At sites of bone injuries, clots with thinner, 
branched fibers may trap more thrombin, increasing the possibility of re-thrombosis or extending the 
duration of hematoma if the primary clot is compromised (Wolberg, 2007). 
 
2.7 PRPs and PRFs in fracture healing 
Platelet-rich plasma (PRPs) was introduced in 1998, by Marx et al. to enhance bone formation (Marx et 
al., 1998). Theoretically, PRP can interact with thrombin at fracture sites, forming a fibrin clot with an 
enrichment of growth factors and with chemotactic and mitogenic properties that are responsible for 
cellular biological functions (Anitua et al., 2007). There was evidence of significantly improved bone 
healing using PRPs (Hanna et al., 2004; Kassolis et al., 2005; Lekovic et al., 2002; Man et al., 2001), 
but other groups reported there was no correlation between new bone formation and the application of 
PRPs due the rapid release of growth factors (Aghaloo et al., 2002; Jakse et al., 2003; Raghoebar et al., 
2005). In 2001, platelet-rich fibrin (PRFs), was introduced as a second generation of platelet 
concentrate by Choukroun et al (Naik et al., 2013). It is thought that PRFs are have a more sustainable 
impact on promoting bone regeneration by having a slower release rate of growth factors compared to 
PRPs (He et al., 2009; Saluja et al., 2011). Some researchers have suggested that the effectiveness of 
PRF in bone regeneration can be attributed to properties such as (1) no use of anticoagulants or 
biological additives in its manufacturing process; (2) slow fibrin polymerization in fibrin fiber network 
formation; (3) the 3-D fibrin structure in PRF forms a fibrin matrix that better retains growth factors 
and releases them over a longer period; (4) an absence of any immune reactions since the blood is 
sourced from the patient (Kumar et al., 2013; Naik, et al., 2013).  
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In terms of structural properties, some researchers have speculated that the fibrin meshwork in RPFs 
contains a high preponderance of equilateral junctions that forms a flexible and elastic clot that aids the 
cytokine enmeshment and cellular migration, whereas in PRPs there are a massive number of bilateral 
junctions forms a tight fibrin network that hinders cellular activities and cytokine attachments (Dohan 
et al., 2006; Dohan Ehrenfest et al., 2009). A recent study was conducted into the clot structure 
morphologies of PRP and PRF made from dog blood using scanning electron microscope (Hatakeyama 
et al., 2014). This comparison showed a regular and dense fibrin network in RPFs, compared which an 
irregular and sparse fibrin network of PRPs (Figure 2-4). This property of PRFs was considered to be 
responsible for the sustained growth factor release that can initiate bone regeneration. 
 
Figure 2-4: Rat PRP and PRF. 
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 (A) PRP formed by activating rat blood with calcium and thrombin. (C) PRF formed from rat blood after centrifugation. (B, 
D) SEM (×10,000) shows details of clot constituents such as platelet aggregates and fibrin fibers. (B) Activated platelets 
and cells (erythrocytes and leucocytes) can be seen entrapped within the fibrin network of the PRP. (D) In the PRF a highly 
dense fibrin network can be seen composed of fibrin bundles and aggregated platelets. P = platelet aggregates and E = 
erythrocytes. 
  
One study found that the morphological and biomechanical properties of PRP, when altered by addition 
of leukocytes, severely decreased in vitro proliferation of human alveolar osteoblasts and fibroblasts, 
indicating that a porous leukocyte-PRP fibrin scaffold may impede tissue regeneration due to changes 
to the fibrin structure and excessive inflammation reactions (Anitua et al., 2015). This contrasted with 
another report that showed that when PRPs were placed in the fracture site they enhanced local 
mechanical properties, which led to improved fracture healing in a rat model (Gandhi et al., 2006). 
Another study that looked into PRFs put forth the proposition that the higher mechanical strength of 
PRFs (Young’s modulus) provided a potential for accelerating bone healing in orthopedic surgery 
(Lucarelli et al., 2010). However, to date there are no studies that make a direct comparison between 
PRF and PRP related to differences in structural properties, such as fiber diameter, density, porosity, 
and branch points.  
PRF has been shown to act as a robust enhancer of proliferation and mineralization and promotes in 
vitro migration of human alveolar bone marrow stem cells (Kang et al., 2011). A similar finding has 
been replicated with rat bone marrow cells exposed to PRP gels, which also promoted the proliferation 
and differentiation of the cells (Van den Dolder et al., 2006). The rate of release of platelet-derived 
growth factor (PDGF), TGF-β, and Insulin-like growth factor (IGF-1) from PRF is significantly slower 
compared to PRPs, suggesting that the 3-D fibrin matrix in PRFs can sequester these growth factor for 
a relatively long time (Gassling et al., 2009).  
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PRPs have been shown to enhance soft tissue repair in animal models, such as rats (Aspenberg et al., 
2004; Kaux et al., 2012; Wnuk et al., 2012), rabbits (Dragoo et al., 2012; Harris et al., 2012; Lyras, 
Kazakos, Verettas, Botaitis, et al., 2009; Lyras, Kazakos, Verettas, Polychronidis, et al., 2009), dogs 
(Hernandez-Martinez et al., 2012; Xie et al., 2013), sheep (Sarrafian et al., 2010), and horses (Bosch et 
al., 2011), but there are also other reports that PRPs had no impact in improving hard or soft tissue 
healing in rats (Beck et al., 2012; Spang et al., 2011) or rabbits (Sato et al., 2012). Similarly, PRFs have 
been shown to significantly promote bone regeneration but only in combination with Bio-Oss on bone 
defects in the calvarias of rats (Oliveira et al., 2015). Interestingly, the implantation of lyophilized 
PRFs has shown to be more a potent remedy for craniofacial bone regeneration in mice and rats, 
possibly because of having up to 13 fold larger pores compared to fresh PRFs (Li et al., 2014). It has 
also been reported that PRFs could promote the cartilage reconstruction in rabbits (Guler et al., 2015), 
which adds to its list of advantages. These studies when viewed together support the view that the 
fibrin clot network can have an impact on a series of biological events at the fracture site, such as, 
cytokine entrapment and cellular infiltration, thereby positively promoting different outcomes in bone 
healing.  
 
2.8 Clinical implications 
Until quite recently, the importance of the structural properties of ﬁbrin clots formed at the sites of 
injury on wound healing was not fully appreciated (Laurens, et al., 2006). It has been documented that 
the structural properties of fibrin clots can significantly influence the initiation of the bone healing 
process. For example, an in vivo study which compared two fibrin-filled scaffolds with different pore 
sizes, formed by low (1.75 NIH U/ml) and high (220 NIH U/ml) concentrations of thrombin, showed 
evidence of delayed healing by day 11 in a 2.3 mm diameter hole of the femoral mid-diaphysis rat 
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model, compared to the control group (Karp et al., 2004). We have performed in vitro studies, the 
results of which suggest that the surface chemistry of biomaterial implants is a key initiator of blood 
coagulation, which can alter clot structure and ﬁbrinolytic activity, thereby controlling release of 
growth factors that is tightly associated with bone healing process (Shiu et al., 2014a). Indeed, 
components of biomaterial implants are likely to be involved in a peri-implant clot formation that 
closely mimics a fracture hematoma, and this could be a valuable in prompting bone healing and 
formation in synthetic bone substitute biomaterials (Shiu et al., 2014b). Evidence for this was 
demonstrated in an in vitro study in which blood clots around biphasic calcium phosphate (BCP) 
microparticles resulted in a more pronounced osteogenic effect compared to control groups (Mouline et 
al., 2010). 
A ﬁbrin mesh is the main constituent of fracture hematoma (Echeverri et al., 2015). There is also a 
temporal component to the healing properties of the fracture hematoma.  Four-day hematomas from rat 
femur fracture sites transplanted into intramuscular sites could generate fresh bone, whereas two-day 
hematomas failed to do so (Mizuno et al., 1990), which is a strong indication that hematomas must 
“mature” before they are capable of contributing to the bone healing process. In rat osteotomy model, 
autologous peripheral blood clots as a carrier of BMP mimicking in situ hematomas have achieved 
complete bone healing (Preininger et al., 2012). In clinical practice, several treatment strategies have 
been proposed for the use of fibrin biomaterials that mimics the structure of natural hematomas. For 
example, PRPs have been incorporated into autologous bone grafts to enhance bone growth in spine 
fusions (Bose et al., 2002; Hee et al., 2003) and it has also been used in combination with 
hydroxyapatite to successfully treat intrabony periodontal defects in humans (Okuda et al., 2005). 
Another example is the combination of autologous human MSCs with PRF, which achieved improved 
therapeutic outcomes in 8 adult patients with bone non-unions in upper extremity by the end of a 76 
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months follow-up study (Giannotti et al., 2013). PRPs were used with patients undergoing total knee 
arthroplasty (TKA), all of which experienced a significantly increase in bone and soft tissue healing 
(Berghoff et al., 2006). On the other hand, some common clinical medications have been listed and are 
associated with bone healing via modulation the quality of blood clot (Table 2-1).  
Chapter 2: Review Paper 
 
                                                                                 
63 
Table 2-1: Drug-related modulation of fibrin clot structure on bone healing 
Medicine name Main clinical use Effect on fibrin clot structure Mechanism Effect on bone healing 
Low molecular 
weight heparin  
Anticoagulant +  
anti-inflammation 
Increasing clot rigidity with thin 
fibers 
Inhibit thrombin 
(Yeromonahos et al., 2012) 
Impair bone healing (Street et 
al., 2000); No impact on bone 
healing (Dalteparin) (Hak et 
al., 2006) 
Unfractionated 
heparin 
Anticoagulant +  
anti-inflammation 
Increasing clot porosity with thick 
fibers (low dose); 
Increasing clot rigidity with thin 
fibers (High dose) 
Inhibit thrombin (Collen et 
al., 2000) 
Delay bone healing (high dose) 
(Kock et al., 2002) 
Warfarin Anticoagulant Increasing clot permeability 
(Blomback et al., 2011) 
Inhibit vitamin K thereby 
reducing synthesis of factor 
II, VII, IX, and X (Lindner et 
al., 2008) 
Impair bone healing (Sugiyama 
et al., 2007) 
Aspirin Anticoagulant +  
anti-inflammation 
Increasing clot permeability and 
fiber turbidity  
Inhibit XIII activation and 
fibrinogen oxidation (Ajjan et 
al., 2009) 
Delay bone healing (325mg) 
(Lack et al., 2013) 
GSNO Antithrombotic 
agents 
Increasing fiber diameter and 
larger pore size (Bateman et al., 
2012) 
Enhance αC region functions 
(Geer, et al., 2008) 
Increase bone mass (De 
Menezes et al., 2012) 
Quinapril Hypertension 
treatment 
Increasing clot permeability Decrease the formation of 
thrombin (Undas et al., 2006) 
Increase bone mass for 
hypertensive populations 
(Perez-Castrillon et al., 2003) 
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Metformin Diabetes (type II) 
treatment 
Increasing clot permeability Enhance lateral aggregation 
of protofibrils, and inhibiting 
thrombin cleavage 
(Standeven et al., 2002) 
No impact on rodent bone 
fracture in vivo (Jeyabalan et 
al., 2013); Promoting 
osteogenic effect both in vivo 
and in vitro (Molinuevo et al., 
2010) 
Simvastatin Anticoagulant + 
Lowering cholesterol  
Increasing clot permeability Decrease the formation of 
thrombin (Undas et al., 2011) 
Enhance bone healing (Patil et 
al., 2009; Skoglund et al., 
2002) 
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In summary, blood clots stand out as being the best natural scaffold for bone defect healing. 
Investigating the molecular mechanisms of ﬁbrin polymerization and clot structural properties would 
aid in the development of blood-based natural scaffolds for clinical use. Identifying structural 
properties of ﬁbrin clot formation, such as crosslink density, fiber diameter, and pore size, would point 
towards approaches to modulate hematomas in preparation for implantation into large bone defects to 
facilitate new bone formation. Should this concept prove efficacious, clinicians will have at their 
disposal a cheap and reliable material with which to heal large segmental bone defects and eliminate 
the need for biologics such as bone morphogenetic proteins. Such a method represents a more natural 
treatment strategy than what is currently available and would offer significant cost savings. Most 
importantly, it would eliminate the many adverse side effects associated with high doses of growth 
factors. Future studies are required to characterize the initial fracture hematoma more thoroughly, in 
order to better understand its inherent structure. This knowledge would inform the development of new 
fibrin-based biomaterials which would be used to effectively treat patients with recalcitrant bone 
defects, especially for delayed-healing or nonunions. 
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Abstract 
 
The importance of hematomas in the bone healing process is well documented. Hematoma formation 
occurs when plasma fibrinogen is activated by thrombin to form fibrin fibers. Fibrin clot properties, 
such as fiber thickness and density, can influence bone repair by impeding the timely progress of 
angiogenesis and migration of mesenchymal progenitor cells and lead to delayed healing. Here, we 
show that clots in large delayed healing bone defects had thinner and more densely packed fibers 
compared with clots in normal healing defects. The proinflammatory cytokine interleukin 1 beta (IL-
1), in particular, was expressed at significantly higher levels in the large defects. We showed that IL-
1β could directly influence fibrinogen molecular assembly without affecting thrombin activity. When 
large bone defects were treated with s-nitrosoglutathione (GSNO) in vivo, this resulted in thicker fibers 
and a more porous clot structure and greatly improved bone healing. In conclusion, this study provides 
evidence to suggest that hematoma structure directly influences bone healing and that manipulating the 
structural properties of blood clots could be a viable therapeutic approach to enhance bone regeneration 
in recalcitrant large bone defects. 
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3.1 Introduction 
 
The clinical management of patients with critical sized bone defects represents one of the most 
challenging problems facing orthopaedic surgeons. The physiological process of bone healing consists 
of three consecutive and overlapping stages: the reactive phase includes hematoma (blood clot) 
formation and inflammatory reaction; the reparative phase includes soft and hard callus formation; and 
is followed by the bone remodelling phase (Wang et al., In press). The late stages of bone healing have 
been well documented but very little is known about the initial stages of the healing process, the 
hematoma formation stage. The importance of early fracture hematoma and its role in fracture healing 
was demonstrated in a study in which the removal of the fracture hematoma resulted in impaired bone 
formation (Grundnes et al., 1993). It is now thought that hematoma formation activates a cascade of 
biological events that serves as a temporary reservoir for the slow release of growth factors and 
provides an appropriate space that assists with cell infiltration, proliferation and subsequent cell 
differentiation.  
The process of hematoma formation occurs when fibrinogen (a plasma protein) is activated by 
thrombin to form fibrin fibers. Bleeding within the fracture site is considered to be the main trigger and 
driver of the coagulation cascade and is an extrinsic pathway, of which thrombin generation is the final 
product (Huber-Lang et al., 2013). Following this, thrombin cleaves two pairs of fibrinopeptides in the 
plasma protein fibrinogen to form protofibrils in the initial fibrin polymerization process, which further 
polymerizes into a fibrin mesh (Guthold et al., 2007). The hematoma (fibrin clot) acts as an initial 
scaffold for growth factor binding and mesenchymal stem cell harboring and migration. Fibrin clot 
properties, such as porosity and thickness of fibrin fibers, can influence bone repair outcomes; for 
example, in vitro fibrin scaffolds formed by thrombin have a small pore size which delays healing 
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when implanted in the rat (Karp et al., 2004), possibly due to low porosity within the fibrin structure 
impeding cell penetration (Vairaktaris et al., 2007). Findings such as these led to the development of 
platelet rich fibrin (PRF), to act as a de facto 3D scaffold to enhance bone regeneration, since its 
regularly formed fibrin network supports cellular migration and sequesters growth factor release 
(Hatakeyama et al., 2014). However, in spite of the recognised importance of the hematoma in the 
fracture healing process, no studies have so far investigated how the structural properties of hematomas 
affect the healing outcomes of bone defects. 
In early stages of bone fractures, an inflammatory response, characterized by the coagulation cascade, 
neutrophil activation, and the complement system, is the first line of defence of the innate immune 
response (Keel et al., 2005). Inflammatory cytokines are some the key mediators involved in 
coagulation activation. Under normal circumstances, the natural anticoagulant mechanisms provide a 
potent defence against thrombotic complications. Inflammatory mediators can elevate platelet count 
and reactivity, and downregulate natural anticoagulant mechanisms to initiate the coagulation system 
and facilitate propagation of the coagulant response, as well as impair fibrinolysis (Esmon, 2005). 
There is a burst release of pro-inflammatory cytokines from neutrophils, monocytes, macrophages, and 
stimulated platelets, which all participate in the clotting process (Wang et al., 2016). The direct 
relationship of pro-inflammatory cytokines with fibrin clot properties is still unclear. 
S-nitrosoglutathione (GSNO) is a s-nitrosated derivative of glutathione and is reported to decrease 
coagulation and thrombosis by limiting platelet activation (Riba et al., 2004; Root et al., 2004). Beyond 
its inhibitory effects on platelets, GSNO has been shown to increase fiber diameter through enhanced 
formation of αC polymer between protofibrils, which leads to a ‘coarse’ fibrin meshwork that is more 
susceptible to fibrinolysis (Akhter et al., 2002; Bateman et al., 2012). GSNO administrated through 
intragingival injections has been used to reduce bone destrcution caused by excessive inflammation 
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seen in periodontitis in a rat model (de Menezes et al., 2012). In clinical practice, GSNO has been 
tested for potential therapeutic uses of anti-platelet actions in obstetrics, respiratory disease, myocardial 
infarction, antimicrobial therapy, and gastroenterology (Alonso et al., 2003; Langford et al., 1996; 
Richardson et al., 2002). 
In this study, we hypothesise that delayed bone defect healing may fundamentally stem from the 
quality of hematoma structure that is formed immediately after an injury. We also explored the role of 
the pro-inflammatory cytokine IL-1β in shaping the structure of the fracture hematomas. Finally, we 
tested whether manipulating the fibrin structure with GSNO could accelerate and enhance fracture 
healing. 
 
3.2 Materials and methods 
3.2.1 Materials used for this study 
Human Fibrinogen (FIB 1) and Human Alpha Thrombin (HT 1002a) were from the Enzyme Research 
Laboratories (Bulimba, QLD, Australia). Human fibrinopeptide A (F3254), human fibrinopeptide B 
(F3379), GSNO were from Sigma Aldrich (Sydney, NSW, Australia). Zorbax 300SB-C18 Analytical 
HPLC Column (5 µm, 4.6 x 250mm) was purchased from Agilent Technologies (Santa Clara, United 
States) and human Fibrinogen (Oregon Green™ 488 Conjugate) and Interleukin-1β was obtained from 
Life Technologies (Mulgrave, VIC, Australia).  
  
3.2.2 Hematoma characterization in bone defect healing 
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3.2.2.1 Animal and surgical procedures 
Sixty-six inbred male Fisher rats, weighing approximately 250 g each, were purchased from the Animal 
Resources Centre (Murdoch, WA, Australia) and housed at the Medical Engineering Research Facility 
of Queensland University of Technology (QUT). The animals were anaesthetised using isoflorane and 
a bone defect, 1-mm in diameter and 2-mm deep, was created in the medial condyle of left femur with 
a Busch cross cut bur (Australian Jewellers Supplies Pty Ltd., Australia). In order to prevent thermal 
necrosis, the operating area was liberally irrigated with a 0.9% saline. A 3-mm diameter defect, also 2-
mm deep, was created in the right femur of the same animal using the same procedure. The skin was 
sutured by wound clips after surgery.  
The antibiotic of Gentamycin (5 mg/kg) was administered intra-muscularly and Cephalothin (25 mg/ml) 
was used to avoid any infection in the wound after surgery. Buprenorphine (0.05 mg/kg) was given to 
rats intraperitoneally twice for 48 h post-surgery to reduce pain. All the animals were monitored daily 
following the surgery for any signs of abnormality, including behaviour, weight loss, and food intake. 
The rats were euthanized in batches at days 1, 4, 7, and 28 post-surgeries. 
 
3.2.2.2 Microtomograhy & Histology 
Day 7 and 28 bone defect samples were harvested and the surrounding soft tissues removed and the 
samples fixed in 4% paraformaldehyde (PFA) (pH=7.4) for 24 h at 4°C. The samples were analysed by 
micro-CT scanning (μCT 40, Scanco) to evaluate mean bone mineral density and bone volume in the 
bone defects. Following the scans, the specimens were decalciﬁed in 10% Ethylene-Diamine-
Tetraacetic Acid (EDTA) solution over a 4 week period at 4℃, after which they were dehydrated and 
embedded in paraffin. Longitudinally sections were cut to a 5 μm thickness using a microtome (Leica 
Microsystem, Germany). All sections were de-waxed, rehydrated, and stained by Safranin O following 
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standard protocol (Rosenberg, 1971). Images of the sections were captured using a Leica SCN400 
Slider Scanner (Leica Microsystem, Germany). 
 
3.2.2.3 Scanning electron microscope 
To analyse the fibrin structure of the blood clot structures in the bone defect sites, the hematomas were 
washed by phosphate buffer solution (PBS) at least 3 times, and then fixed in 3% glutaraldehyde 
overnight. Specimens were transferred into a PBS solution to probe the unprocessed clot structures 
without dehydration using a TM3000 scanning electron microscope (SEM; Hitachi Corporation, Japan). 
Images were captured at the edge and the centre of the hematomas 50× and 1000× magnification at the 
high voltage (HV) range of 15 kV. 
To probe the fine detail of the fibrin structure, glutaraldehyde fixed 1 and 4 day samples were 
transferred to 0.1 M cacodylate buffer and fixed in 4% osmium, and dehydrated using 50%, 70%, 90%, 
and 100% ethanol. The samples were dried by hexamethyldisilazane solution in a fume hood, then 
mounted on carbon tabs and sputter coated with gold-palladium (Lai et al., 2010; Shiu et al., 2014). The 
structure of the blood clots were analysed using Quanta200 SEM (Zeiss, FEI, USA) at 5000× 
magnification with a working distance of 10 mm to view more specific features of the fibers. Images 
captured from the edges of the hematomas were used for fibrin fiber diameter and density 
measurements. Quantitative fibrin network analysis was performed using Image J software (version 
1.43) (Undas et al., 2008). 
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3.2.2.4 Real-time quantitative polymerase chain reaction (RT-PCR)  
A batch of 6 rats was euthanized at day 1 post-surgery for RNA extraction from the defect sites. The 
hematomas with surrounding bone tissues were harvested and immersed in RNA later® solution (Life 
Technologies) for RNA stabilization and stored at -80°C. Total RNA was isolated using Trizol reagent 
(Life Technologies) and 500 ng of total RNA used as template for reverse transcription using a 
DyNAmo kit (Thermo Scientific). RT-qPCR was performed using SYBR Green qPCR Master Mix 
(Life Technologies) on an ABI Prism 7500 Thermal Cycler (Applied Biosystems, Foster City, 
California, USA). All primer sequences (Supplementary Table 3-1) were analysed for target 
specificity on Primer BLAST and were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). 
The mRNA expression of the genes of interest was normalized against the housekeeping gene GAPDH. 
The difference between the mean Ct values of the gene of interest and the housekeeping gene was 
labelled ΔCt and the relative expression was calculated using the formula 2(-ΔCt ) x104, modified from 
(Bookout et al., 2003). 
 Genes Forward sequences (5’-3’) Reverse sequence (5’-3’) 
IL-1β TAAGCCAACAAGTGGTATTC AGGTATAGATTCTTCCCCTTG 
IL-6 CAGAGTCATTCAGAGCAATAC CTTTCAAGATGAGTTGGATGG 
IL-10 TCTCCCCTGTGAGAATAAAAG  TAGACACCTTTGTCTTGGAG  
TNF-α CTCACACTCAGATCATCTTC AGAACCTGGGAGTAGATAAG 
GAPDH AGATCATCAGCAATGCCTCCTGC ATGGCATGGACTGTGGTCATGAG 
 
Table 3-1: Primer sequences used for real time quantitative PCR analysis 
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3.2.2.5 Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
The harvested fracture hematomas were transferred into 150 µL RIPA lysis buffer (50 mM TRIS.HCl 
pH 7; 150 mM NaCl; 0.1% SDS; 0.5% sodium deoxycholate; 1 mM PMSF) and homogenized using a 
Mini-BeadBeater (Biospec Products, Inc., Bartlesville, Okla.), then incubated on ice for 20 mins. The 
cell lysates were clarified by centrifugation for 5 mins at 5,000×g, 4°C, and the supernatants transferred 
into fresh microcentrifuge tubes and further purified by centrifugation at 18,000×g, for 15 mins at 4°C). 
Protein concentrations were quantified using a Bicinchoninic Acid (BCA) Protein Assay kit (Pierce, 
Thermo Scientific). The levels of inflammatory cytokines were measured using commercial 
chemiluminescence-based ELISA (R&D Systems, Inc., Minneapolis, MN), following the 
manufacturer’s instructions. The cytokine concentrations were determined by correlation with a 
standard curve and the outcomes were expressed as the amount (pg) per millilitre of supernatants. Each 
experimental condition was assayed at least six times. 
 
3.2.3 In vitro fibrin clot characterization 
3.2.3.1 Turbidity measurement 
Fibrin polymerization was monitored in a Nunclon Delta 96-Well MicroWell Plate (Thermo Scientific, 
USA) by recording the alterations in turbidity at 405 nm (A405) every 15 seconds for 50 mins at 37°C 
using a Microplate Absorbance Reader (Bio-Rad X-Mark spectrophotometer) as described previously 
(Konings et al., 2011; Zucker et al., 2014). Hundred microliters of purified fibrinogen (1 mg/mL), with 
or without IL-1β (at 50 or 500 pg/mL), in HEPES buffer (20 mM HEPES, 150 mM Nacl, PH=7.4) was 
incubated for 10 mins at 37°C. Thrombin (0.5 U/mL) and CaCl2 (1 mM) were mixed and incubated at 
37°C for 10 mins then added to the fibrinogen solution. The lag time was an indicator of the rate of 
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protofibril formation, with the maximum slope line representing the maximum rate of lateral 
aggregation (Vmax), which was determined using 6 points on the polymerization curve. The maximal 
turbidity reflected the size and number of fibers. Five replicates were performed for each experimental 
condition. 
 
3.2.3.2 Scanning electron microscopy 
Fifty microliters of purified human fibrinogen (1 mg/mL), with or without IL-1β (at 50 or 500 pg/mL), 
in HEPES buffer containing human thrombin (0.5 U/mL) was mixed with CaCl2 (10 mM). In vitro 
fibrin clots were allowed to form overnight at room temperature. The fiber diameter and density were 
analysed using SEM (Zeiss, FEI, USA) at 10,000× magnification. 
 
3.2.3.3 Confocal microscopy 
Fifty microliters of fibrinogen (1 mg/mL), with or without IL-1β (at 50 or 500 pg/mL), in HEPES 
buffer was spotted out on microscope coverslips (ProSciTech, QLD, Australia) together with Oregon 
Green™488 fibrinogen (0.1 mg/mL). Clots were formed in a moist atmosphere overnight at room 
temperature after the addition of 0.5 U/mL thrombin and 10 mM CaCl2. The coverslips were mounted 
on a microscope slide and the clots analysed using a Nikon A1R Confocal Microscope equipped with a 
40X NA oil immersion objective lens. The scan format was set to 1024×1024 pixels. The pinhole set to 
one Airy unit to obtain maximum resolution in the z-plane. Fiber diameters were measured using the 
A1R proprietary software. The scans were taken under 6x zoom-in mode and the fibrin structures 
characterized by 2D and 3D reconstructions. After acquisitions of 3D structure (Z stack), maximum 
intensity projections (MIP) images were obtained. Fiber thickness was measured by drawing a 
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perpendicular line across the fiber to avoid any junctions in the MIP images. Ten fiber diameters were 
measured from each scan and the fiber density was calculated as follows: A line of 50 µm was drawn in 
the middle transections of scanned MIP image from right to left and the number of fibers crossing the 
line was counted using the Intensity Profile and Object Count tools, as described previously with some 
minor modifications (Konings, et al., 2011; Metassan et al., 2010). 
 
3.2.3.4 Compaction study 
Compaction assays are used to characterize the rigidity of the fibrin clots by calculating the compaction 
coefficient, which is inversely proportional to Young’s modulus of the fibrin network elasticity (Nair et 
al., 1997; Undas et al., 2010). Four-hundred and fifty microliters of purified human fibrinogen (1 
mg/mL) or citrated rat plasma, with or without IL-1β (at 50 or 500 pg/mL), in HEPES buffer was 
incubated in 0.5 U/mL thrombin and 10 mM CaCl2 in a 2 ml tube. Clots were allowed to form 
overnight at room temperature, then centrifuged at 6,000 g for one minute. The volume of fluid 
expelled from the fibrin network was measured with a 1 mL Terumo Insulin syringe with a 23 G × 1/2" 
needle. Compaction was defined as this volume divided by the initial volume.  
 
3.2.3.5 High Performance Liquid Chromatography (HPLC) 
Firbinopeptide release was measured according to methods described previously (Cooper et al., 2003; 
Geer et al., 2008; Nordstrom et al., 2010). Briefly, 50 µL of thrombin (1 U/mL) was added to 2 mL of 
purified human fibrinogen (1 mg/mL), with or without IL-1β (500 pg/mL), in HBSC buffer (20 mM 
HEPES, 150 mM Nacl, 1 mM Cacl2 at pH 7.4) that was gently mixed by inversion and divided into 250 
µL aliquots. Once the thrombin had been added, care was taken to restrict handling of the sample tubes 
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to as short a time as possible, so that the clotting process was not unduly affected by agitation. Total 
peptide release or no-release control was assayed by the addition of 50 µL thrombin (20 U/mL) to 250 
µL fibrinogen or only fibrinogen for 60 mins, respectively. Polymerization reactions were initiated at 
37 °C using a dry block heater and terminated at 1, 2, 5, 10, 20, and 40 mins by placing each tube in 
boiling water (97-100°C) for 15 mins. The specimens were cooled on ice, and then centrifuged at 
13,000 g for 15 mins at 4 °C and the supernatants passed through 0.2 µm syringe filters and stored at -
80°C. The analysis was performed using a Shimadzu Prominence System HPLC with a 300SB-C18 
Column (4.6 mm × 250 mm, 5 µm, Agilent) at 210 nm. The fibrinopeptide release curves were plotted 
using Kinetic Equations 1 and 2, described by Ng et al (Ng et al., 1993). In both equations, e 
represented thrombin concentration and t the reaction time. The value of k1 was defined as the first-
order rate constant for the release of FpA, whereas k2 was determined as the first-order rate constant for 
the release of FpB (Lord et al., 1996). Buffer A (25 mM NaH2PO4 /Na2HPO4, pH 6.0) was used to 
equilibrate the C18 column and a linear gradient from 0% to 40% of buffer B (25 mM 
NaH2PO4/Na2HPO4, pH 6.0, with 50% acetonitrile) were applied to the eluted fibrinopeptides. 
Equation 1: FpA% = (1 − 𝑒−𝑘1𝑡)  × 100  
Equation 2: FpB% = (1 + [
𝑘2
𝑘1−𝑘2
] 𝑒−𝑘1𝑡 −  [
𝑘1
𝑘1−𝑘2
] 𝑒−𝑘2𝑡) × 100  
 
3.2.4 Effects of GSNO on bone defect healing via modulating fiber thickness 
3.2.4.1 Thromboelastography (TEG) 
The haemostatic profiles of rat whole blood were analysed on a Thromboelastograph Haemostasis 
System 5000 (Hemoscope Corporation), using a modified method described previously (Narain et al., 
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2015; Wohlauer et al., 2011). The rats were euthanized with CO2 and whole blood drawn from the 
hepatic portal vein and mixed 9:1 with 4% trisodium citrate. Two-hundred and eighty microliters of 
citrated blood was mixed with GSNO buffered in deionized water to final concentrations of 0.01, 0.1, 1 
or 10 mM; no GSNO served as controls. The clotting reactions were initiated with the addition of 20 
µL of 0.2 M CaCl2 and the TEG experiments run in the test cups for 1 h at 37°C. The haemostatic 
parameters from standard TEG tracings, including reaction time, coagulation time, alpha angle (α), and 
maximum amplitude (MA) (Figure 3-6A and Supplementary Table 3-2), were recorded and the data 
analysed.   
 
Reaction time (R- time) The time elapsed from initiating the recording until the 
amplitude reaches 2 mm. 
Coagulation time (K- time) The time interval between R and TEG amplitude reaches 20 
mm, indicating the speed of blood clot formation. 
Alpha angle (α) The angle is the inclination from R time value to K time 
value, representing the quality of platelets and fibrinogen. 
Maximum amplitude (MA) MA is an indicator of maximum clot strength, reflecting 
platelet function.  
 
Table 3-2: Thromboelastograph (TEG) parameters 
 
3.2.4.2 Scanning electron microscopy 
Large femoral defects (3-mm-diameter, 2-mm-depth) were created bilaterally in rats under full 
anaesthetics. GSNO at a range of concentrations of (0.1, 1 or 10 mM) were mixed thoroughly with 
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blood within the defects and blood clots allowed to form overnight; no GSNO served at controls. At 
day 1, all the animals were euthanized and the clots harvested and processed as described in section 
2.2.3. Images of structural features of the clots (diameters and density) were captured using the SEM at 
10,000× magnification. Statistical analyses were performed to test for significance.   
 
3.2.4.3 X-ray & Microtomograhy 
Once the delayed bone healing defect had been established, GSNO at defined concentrations (0.1, 1 or 
10 mM) were applied to the defects. The animals were euthanized at days 7 and 28 post-surgery and all 
bone defect specimens, with neighbouring bone tissues, were excised and fixed in glutaraldehyde then 
processed as described above. Bone healing was evaluated using a digital dental x-ray unit (Faxitron 
Bioptics, LLC, Tucson, AZ, USA) and µCT scanner. 
 
3.2.5 Statistical analyses 
Data on fibrin fiber diameters were tested for normal distribution using Kolmogorov-Smirnov test. For 
statistical evaluation, Student’s t test and one-way ANOVA followed by Holm-Sidak post-test was 
used for two and three group differences, respectively. Data for fibrinopeptide release assay were 
analysed using a two-way ANOVA followed by Holm-Sidak post-test. P values of less than 0.05 were 
considered significant. All the statistical analyses were done in GraphPad Prism Version 6.03. Results 
were represented as the means ± standard derivation. 
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3.3 Results 
3.3.1 Evaluation of bone healing in 1 mm and 3 mm bone defects 
 
Figure 3-1: Bone healing in 1 mm and 3 mm defects. 
 (A–D) Micro-CT show defect healing at day 7 and 28 in a 1 mm defect (A, C) and a 3 mm defect (B, D) (scale bar = 1 
mm). (E) Statistical analysis of BT/TV ratios. (F, G) Safranin O staining showed no cartilage in the 1 mm defects, (H, I) 
whereas there was robust evidence of cartilage in the 3 mm defects at day 28 (scale bar = 100 µm). P value was obtained by 
independent sample student’s t test. n = 6. 
 
Bone healing in the 1 mm and 3 mm defects was assessed in rat femur by CT and histological 
analyses. In the 1 mm defect, de novo bone can be seen lining the defect cavity at day 7 (Figure 3-1A). 
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By day 28 the defect was almost completely filled (Figure 3-1C). The 3 mm defect, after 7 days, 
showed evidence of some bone formation around the edge of the defect cavity (Figure 3-1B), whereas 
by day 28 there was evidence of substantial healing (Figure 3-1D). The ratio of bone volume / total 
volume (BV/TV) in the 1 mm defect was 6.13 % ± 0.86 % at day 7, whereas for the 3 mm defect the 
BV/TV was 1.80 % ± 0.61 % (Figure 3-1E), which amounts to a statistically significant difference of 
70.6 % between the 1 mm and 3 mm defects. The corresponding BV/TV ratios at day 28 were 66.01 % 
± 13.57 % in the 1 mm defect and 35.65 % ± 0.85 % in the 3 mm defect (Figure 3-1E), a 46% 
difference between the two treatments. The Safranin O staining showed no detectable cartilage in 1 mm 
defects at 28 days (Figure 3-1, F and G), whereas in the 3 mm defects there was ample evidence of in 
situ cartilage at 28 days (Figure 3-1, H and I). 
 
3.3.2 Morphological differences of hematomas in 1 mm and 3 mm bone defects 
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Figure 3-2: Morphological differences of hematomas in 1 mm and 3 mm bone defects. 
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(A–P) The morphology of hematomas (edge and center region) in 1 mm and 3 mm defects was analysed using TM3000 
SEM at day 1, 4, and 7 (scale bar = 2 mm and 100 µm) (n = 6). This showed that the hematomas in 1 mm defects (A, G, M) 
were both thicker and had a looser configuration compared with those found in the 3 mm defects (D, J, P). (S–V) The 
morphology of the hematoma edges were studied at high magnification using Quanta 200 at day 1 and 4 (scale bar = 20 µm). 
Graphical summary of statistical analyses (student’s t test) of fiber diameter (W) and density (X) from 1 and 3 mm defects 
at days 1 and 4 (n = 6).  
 
The structural morphology of hematomas in the 1 mm (Figure 3-2, A, G, and M) and 3 mm (Figure 3-
2, D, J, and P) defects were analysed using a TM3000 backscatter SEM, focussing on the edge and 
center regions of the samples. There was a discernible difference between the 1 mm and 3 mm 
hematomas, particularly in the later time point. In the 1 mm defect at day 1, small pores (white circles) 
can be seen in the fibrin network at the edge of the hematomas (Figure 3-2C). By comparison, the 3 
mm defect hematoma has a tightly packed fibrin network that is more heavily branched and had a 
greater numbers of fibers (Figure 3-2F). The fibrin architecture at the center of the hematomas of both 
the 1 mm and 3 mm defects were very similar in terms of fiber density and thickness (Figure 3-2, B 
and E). At day 4, the fibrin structure in the 1 mm hematoma showed fibers that were both thicker and 
loosely woven (Figure 3-2, H and I) and there was also evidence of transformation into fibrous tissue 
by the appearance of granulation nodules (Figure 3-2I). By comparison, the 3 mm hematoma showed 
densely packed fibrin fibers at both the center and edge of the clot (Figure 3-2, K and L). By day 7, 
the structural differences between the two treatments were even more pronounced (Figure 3-2, M and 
P). The fibers in the 1 mm hematoma appeared thicker and less densely packed (Figure 3-2, N and O), 
whereas in the 3 mm defect, at both the edge and center, were what appeared to be thin and very 
densely packed fibers (Figure 3-2, Q and R).     
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The hematomas were also analysed under high magnification using a Quanta 200 SEM to quantify 
fiber characteristics near the edges (Figure 3-2, S–V). This analysis revealed that at day 1 the fibers in 
the 1 mm defects were significantly thicker compared with the 3 mm defects (397.58 ± 125.34 nm vs. 
245.76 ± 41.26 nm; P < 0.01). This was also the case in the day 4 samples with the fibers in the 1 mm 
defect measuring 295.72 ± 49.86 nm compared to fibers in the 3 mm defect at 226.16 ± 57.0 nm, (P < 
0.05). The fiber density (measured as fibers per 40 µm2) at the edge of 1 mm defects was 8.65 ± 2.1 
compared to 30.8 ± 3.88 in the 3 mm defects at day 1 (P < 0.001). These figures were comparable to 
the day 4 samples, with the 1 mm defect fiber density estimated at 8.4 ± 1.98 versus 25.8 ± 3.92 in the 
3 mm defect (P < 0.001). These data are summarised graphically (Figure 3-2, W and X).  
 
3.3.3 The effect of IL-1β on fibrin polymerization 
 
Figure 3-3: Effect of IL-1β on fibrin clot polymerization. 
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(A) Representative profiles of clot formation were monitored spectrophotometrically at 405 nm. There were three phases of 
fibrin polymerization: (B) Lag time of protofibril formation, (C) Vmax, and (D) maximal turbidity. P value was obtained by 
one-way ANOVA test with Holm-Sidak post-test and represented mean ± SD. n = 5. 
 
The effects of 50 pg/ml and 500 pg/ml IL-1β (hereafter referred to as 50 pg and 500 pg, respectively) 
on the fibrin polymerization process were assessed in terms of protofibril formation, lateral aggregation, 
and maximum turbidity (Figure 3-3A). The lag time was measured in seconds, from when the turbidity 
rose above 0.001. There was no significant difference in lag times between the control and 50 pg 
groups (P = 0.43), whereas the 500 pg group had a significantly shorter lag time compared to the 
control group at 57.8 s ± 24.6 vs. 143.5 s ± 43.0 (P < 0.01) (Figure 3-3B).  
The Vmax of the control and 50 pg groups showed no significant difference (0.7566 ± 0.0554 vs. 0.7456 
± 0.0349; P = 0.72); Vmax for the 500 pg group was significantly lower compared to controls at 0.6764 
± 0.0456 (P < 0.05) (Figure 3-3C). The shorter lag time and lower Vmax of the 500 pg group were 
indicative of the thinner fibrin fibers in this group. This was also reflected in the maximal turbidity 
(Tmax), which is closely associated with the ratio between fiber mass and length. The value for Tmax in 
the control group was 0.0628 ± 0.0060 compared to 0.0603 ± 0.0013 in the 50 pg group (P < 0.05), 
whereas Tmax in the 500 pg was 0.0588 ± 0.0023 (P < 0.01) (Figure 3-3D). 
 
3.3.4 The effect of IL-1β on fibrin clot architecture 
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Figure 3-4: IL-1β influences fibrin clot architecture. 
(A–I) The morphology of fibrin clot architecture was observed under Zeiss SEM (scale bar = 2 µm) and confocal 
microscopy (scale bars = 10 µm). (J–M) The fiber diameter was significantly decreased and the fiber density significantly 
increased by the stimulation with IL-1β at 500 pg/mL. P value was obtained by one-way ANOVA test with Holm-Sidak 
post-test and represented mean ± SD. n = 3. 
 
SEM and confocal fluorescence microscopy (CM) were used to assess the effects of IL-1 on the 
physical properties of the fibrin fibers. High magnification SEM showed that the control and 50 pg 
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groups had similar fiber diameters at 175.17 ± 38.37 nm and 174.27 ± 41.06 nm, respectively (P = 0.85) 
(Figure 3-4, A, B, and J). By comparison, the fibers of the 500 pg group were significantly thinner at 
75.47 ± 14.33 nm (P < 0.01) (Figure 3-4, C and J). The fiber density (measured as the number of 
fibers per 4 m2) in the 500 pg group was significantly higher compared to the control and 50 pg 
groups at 20.1 ± 1.84 vs. 12.4 ± 2.94 and 11.75 ± 1.44, respectively (Figure 3-4K). CM analysis, using 
both 2D (Figure 3-4, D–F) and 3D (Figure 3-4, G–I) image capture, showed unambiguously higher 
fiber density in the 500 pg group compared to 50 pg and control groups. This analysis also revealed the 
existence of large pores within the fibrin structures of the control groups. Look-up table (LUT) image 
processing was used to minimize colour saturation and noise of the Z-stack MIP images and this 
yielded more reliable fiber size values from the CM analyses. The fiber diameter of the control and 50 
pg groups were estimated at 657 ± 87.75 nm and 590 ± 81.73 nm, respectively (P = 0.11) (Figure 3-
4L). This compared with an estimated fiber diameter of 449 ± 57.70 nm in the 500 pg group (P < 0.01) 
(Figure 3-4L). The Intensity Profile and Object Count tools were used to count the number of fibers, 
which were estimated to be 13.33 ± 1.69 and 12.66 ± 1.98 in the control and 50 pg groups respectively 
(P = 0.71), compared with 19.33 ± 1.25 in the 500 pg group (P < 0.05) (Figure 3-4M). 
 
3.3.5 The effect of IL-1β on fibrinopeptide release 
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Figure 3-5: IL-1β influences fibrinopeptide release. 
Fibrinopeptides release from thrombin-treated fibrinogen with (black dash line) or without (black solid line) IL-1β (500 
pg/mL). Inset shows a normal chromatogram from HPLC, the two major peaks denoted fibrinopeptide A and B that was 
confirmed with standard fibrinopeptide solutions. AP: fibrinopeptide A, phosphorylated; A: fibrinopeptide A; AY: Des-arg-
fibrinopeptide A; and B: fibrinopeptide B. P value was obtained by two-way ANOVA test with Holm-Sidak post-test and 
represented mean ± SD. n = 3 
 
The polymerization reactions were initiated with thrombin and terminated at designated time points. 
IL-1β’s capacity to suppress the catalytic ability of thrombin was measured by the rate of conversion of 
fibrinogens to fibrinopeptide A and B (FpA and FpB) by HPLC analysis. The areas under the curves 
were calculated and showed no significant difference in the amount of FpA or FpB resulting from IL-
1β treatment compared to controls (Figure 3-5), which suggests IL-1β has limited effect on thrombin 
activity. The rate constants k1 and k2 were determined from the amount of FpA and FpB and the 
differences were not significant (P > 0.05) (Supplementary Table 3-3). 
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Supplementary Table 3-3: Rate of Thrombin-catalysed FpA and FpB release a 
 
Experiment 
Control groups IL-1 β groups 
Release rate of FpA 
(k1) 
Release rate of FpB 
(k2) 
Release rate of FpA 
(k1) 
Release rate of FpB 
(k2) 
1 0.0990 ± 0.019 0.020 ± 0.002 0.1486 ± 0.011 0.014 ± 0.002 
2 0.1550 ± 0.008 0.013 ± 0.001 0.1088 ± 0.016 0.020 ± 0.003 
3 0.0828  ± 0.009 0.015 ± 0.001 0.0940 ± 0.013 0.013 ± 0.001 
avg 0.1122 ± 0.034 0.016 ± 0.003 0.1171 ± 0.027 0.016 ± 0.004 
 
The value for FpA was k1 and FpB was k2 and represented the conversion rate of fibrinogen (1 mg/mL) 
by thrombin (1 U/mL) per unit time (min) in the presence and absence of 500 pg/mL IL-1β. 
 
3.3.6 The effect of GSNO on blood coagulation 
Chapter 3: Experimental Paper One
 
                                                                                             
 
111 
 
Figure 3-6: GSNO influences blood clot kinetics. 
(A) A representative coagulation process in TEG was traced using citrated blood from uninfected, normal rats, as shown by 
white lines. (B) Comparison was made between TEG samples with (light green line, 0.01 mM; light red line, 0.1 mM; dark 
red line, 1 mM; and aqua line, 10 mM) or without GSNO (black line, control) (scale bar = 10 mm). NS = no significant 
difference. (C–F) Parameters related to coagulation were statistically compared: reaction time, coagulation time, alpha 
angle, and maximum amplitude. P value was obtained by one-way ANOVA test with Holm-Sidak post-test and represented 
mean ± SD. n = 6. 
 
TEG analysis showed significantly longer R values (measured in seconds) for the 1 and 10 mM GSNO 
treatment groups, respectively at 455 ± 7.1 and 480 ± 21.2, compared to the control at 335 ± 28.3 (P < 
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0.05) (Figure 3-6C). Similarly, the coagulation times (K) were significantly longer for the 1 and 10 
mM GSNO groups, respectively at 275 ± 7.1 and 245 ± 28.3 compared to the controls at 150 ± 21.2 (P 
< 0.05) (Figure 3-6D). The alpha angle (measured in degrees) for 0.1, 1 and 10 mM of GSNO were 
47.3 ± 7.2; 48.5 ± 1.6; 44.8 ± 3.6 respectively and significantly lower than the controls at 67.1 ± 0.3 (P 
< 0.05) (Figure 3-6E). The maximum amplitude (measured in mm) of the 10 mM GSNO samples was 
reduced by 30% compared to the controls (50.5 ± 2.1 vs. 72.6 ± 1.8; P < 0.001), whereas the 0.1 and 1 
mM GSNO samples were reduced by approximately 14% compared to controls (62.5 ± 0.4 and 62.9 ± 
1.3; P < 0.05) (Figure 3-6F).  
 
3.3.7 The effect of GSNO on blood clot structure 
 
Figure 3-7: GSNO influences in vivo blood clot structure. 
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(A) The morphology of day 1 blood clots within the 3 mm defects was observed using SEM (scale bar = 2 µm). (B) GSNO 
was added and mixed with blood in the defects (white arrow head). Blood cells are represented in different colours: aqua, 
erythrocytes (E); orange, leukocytes (L); and yellow, platelets (P). (C, D) Fiber thickness and density were calculated and 
analysed. NS = no significant difference. P value was obtained by one-way ANOVA test with Holm-Sidak post-test and 
represented mean ± SD. n = 3. 
 
We analysed the in vivo effect of GSNO on blood clot structure in bone defects using SEM (Figure 3-
7A). There was a significant increase in the ﬁber diameter when GSNO was applied to the induced 
defects (Figure 3-7B). The mean ﬁber diameter in the controls was 245.8 ± 41.7 nm compared to 316.9 
± 104 nm in the 0.1 mM GSNO and reached a maximum of 596.6 ± 249.4 nm in the 1 mM GSNO 
samples (P < 0.01); there was a sharp decrease to 189.7 ± 47.8 nm with 10 mM GSNO (P < 0.05) 
(Figure 3-7C). In spite of the fiber thickness increasing in the 0.1 mM GSNO group, the fiber density 
remained unaffected compared to the controls (18.0 ± 2.7 vs. 13.8 ± 5.4; P > 0.05). By comparison, the 
fiber density was significantly decreased in the 1 mM GSNO samples at 5.2 ± 2.3 (P < 0.01) and was 
reduced to near zero in the 10 mM GSNO group (P < 0.01) (Figure 3-7D). 
 
3.3.8 The effect of GSNO on large bone defect healing 
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Figure 3-8: GSNO influences in vivo large bone defect healing. 
Representative radiographs at day 7 and 28. (A) X-ray pictures were taken of the femurs of each rat. The defects were 
highlighted by colours (yellow = control, white = 0.1 mM GSNO, purple = 1 mM GSNO, and blue = 10 mM GSNO). (B) 
BV/TV data were calculated from µCT scans of each rat. NS = no significant difference. P value was obtained by one-way 
ANOVA test with Holm-Sidak post-test and represented mean ± SD. n =3 
 
The effect of GSNO on bone repair in large defects at 7 and 28 days was evaluated by standard X-ray 
imaging and CT scans (Figure 3-8, A and B). Analysis of de novo bone formation at 7 days showed 
significantly increased BV/TV ratios in both 0.1 and 1 mM GSNO treatments groups at 15.41 % ± 
1.24 % and 18.35 % ± 1.34 %, respectively, compared to the control groups at 6.84 % ± 0.59 % (P < 
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0.01). By contrast, the BV/TV ratio fell in the 10 mM GSNO groups relative to the 0.1 and 1 mM 
treatment groups but was still significantly higher than the controls at 10.39 % ± 2.16 %  (P < 0.05) 
(Figure 3-8B). The trend of the BV/TV ratios was similar at 28 days, which saw the largest increase in 
the 1 mM GSNO treatment group (63.72 % ± 14.13 %), followed by 0.1 mM GSNO (55.17% ± 
11.05 %), compared to the controls (36.65 % ± 1.04 %) (P < 0.05). Bone formation was also up in the 
10 mM GSNO treatment group relative to the controls (38.64 % ± 6.43 %) but failed to reach 
significance (Figure 3-8B). 
 
3.4 Discussion 
Bone fracture healing is a unique physiological process that does not involve the formation of fibrous 
scar tissue. Instead, skeletal bones heal through a process that recapitulates aspects of embryonic 
skeletal development (Gerstenfeld et al., 2003). However, large segmental defects, frequently caused 
by traumatic injuries, severely challenge the natural healing capacity of bone. In such cases the repair is 
often unsatisfactory, resulting in delayed healing or non-healing with considerable morbidity for 
patients. Fracture hematoma formation, which occurs within minutes of a bone injury, is a cascade of 
biological events that include activated coagulation factors in the hematological system, as well as a 
large number of other factors derived from the periosteum and surrounding soft tissues, such as 
osteogenic, angiogenic and other growth factors, and pro-inflammatory cytokines (Horst et al., 2015). 
The primary role of the hematoma is to seal the wound to prevent further blood loss and also act as a 
natural biological ‘scaffold’ providing a temporary fibrin matrix for the migration, attachment, and 
differentiation of osteogenic cells (Echeverri et al., 2015). Removing fracture hematomas at days 2 and 
4 seriously affects bone healing in a rat femoral fracture model (Grundnes, et al., 1993). Similarly, 
delayed bone healing ensued when the hematomas in open osteotomies in the middle tibia of rabbits 
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were repeatedly removed by irrigation and debridement (Park et al., 2002). These and similar findings 
indicate that stable hematomas are crucial for initial bone healing (GÜNAY et al., 2013; Van der Ende 
et al., 2013). 
The adverse effect of impaired fracture hematomas on bone repair is now widely recognized (Harwood 
et al., 2010); however, in spite of this, the structural properties of hematomas have received only scant 
attention. Much of our knowledge of the fracture hematoma has been derived indirectly from analysis 
of its supernatant. Properties such as low pH, high phosphate, alkaline phosphatase, and lactate values 
were interpreted as evidence of low oxygen tension (Kolar et al., 2010) and this has later been 
confirmed in animals models (Aro et al., 1984; Epari et al., 2008). The hypoxic environment of the 
hematoma leads to a dramatic upregulation of vascular endothelial growth factor (VEGF), measured at 
nearly 15-fold greater concentrations within the early fracture hematoma compared to the plasma. 
Paradoxically, the viability of both endothelial and osteoblast cells are significantly reduced when 
grown in supernatants from fracture hematomas, an effect that has been ascribed to a high 
concentration of potassium ions within the hematoma (Street et al., 2000). Cell composition analysis of 
a middle shaft osteotomy defect model in sheep show there is a higher proportion of lymphocytes than 
granulocytes early (1 to 4 hours) in induced hematomas (Schmidt-Bleek et al., 2009). Inflammatory 
cells control and coordinate fracture healing and T cells, in particular, are important for the resolution 
of the inflammation by secreting anti-inflammatory cytokines such as IL-10 (Schmidt-Bleek et al., 
2014). TNF- is another cytokine that is needed to direct migrating bone marrow stromal cells 
(BMSCs) towards osteogenic differentiation by inducing bone morphogenetic protein-2 (BMP-2), an 
essential factor in bone regeneration (Hess et al., 2009). Revascularization of the granulation tissue that 
forms within the blood clot is also an important facet of the healing process and the gene expression of 
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angiogenic factors such as vWF, Ang1, Ang2, VEGF, CYR61, FGF2, MMP2, and TIMP1 are reported 
to be lower in delayed bone healing in a sheep model (Hess, et al., 2009).  
In this study, we describe the application of a simple model of normal and delayed healing bone defects 
in rats and the evaluation of these defects using micro-CT, scanning electron microscopy, histology, 
and Safranin O staining. A striking feature of the early fracture hematomas (day 1) in the 1 mm defects 
was the appearance of small pores in the fibrin network near the edge of the hematomas, whereas the 3 
mm defects were characterised by a tight fibrin network. The tight fibrin network of the 3 mm delayed 
healing defects were associated with thinner fibers, in contrast to the 1 mm normal healing defects 
which had a loose fibrin structure with thicker fibers. We also performed assays to determine what 
biological factors might influence the different fibrin structures and detected differential expression of 
inflammatory cytokines between the two defect sizes. Cytokines are released from activated platelets 
and other blood cells and are directly involved in the coagulation cascade during the early stages of 
hematoma formation (Morrell et al., 2014). IL-1β had by far the highest mRNA expression compared to 
other inflammatory cytokines. There was a 2-fold increase of IL-1 mRNA in the 3 mm defect relative 
to the 1 mm defect (Supplementary Figure 3-9A). When comparing IL-1 against the other cytokines, 
we found a 16-fold higher expression of IL-1 in the 1 mm defects relative to IL-6 and a 9-fold higher 
expression in the 3 mm defects. The difference in mRNA expression of IL-1 relative to IL-10 and 
TNF- was more than 30-fold higher (Supplementary Figure 3-9A). The protein expressions of IL-1β 
mirrored the mRNA expression, whereas the other inflammatory cytokines (IL-6, IL-10, and TNF-α) 
were undetectable by ELISA (Supplementary Figure 3-9B). In plasma, normal concentrations of IL-
1β is 0.6 pM (approximately 10 pg/mL) (Sahni et al., 2004). By comparison, we recorded IL-1β levels 
in the 3 mm hematoma as high as 745.40 ± 99.19 pg/mL.  
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Fibrinogen, a 340 kDa glycoprotein clotting factor, consists of two sets of three paired polypeptide 
chains (AαBβγ)2 (Jennewein et al., 2011). The fibrinogen molecule includes a central nodule, two 
coiled-coils, the β and γ nodules, and αC regions tethered to the central nodule (Weisel et al., 2013). In 
the process of fibrin polymerization, thrombin cleaves the α-subunit of fibrinogen to release 
fibrinopeptide A (FpA) and generates the fibrin monomers (αBβγ)2 (termed as FIm), which can 
polymerize to unstable fibrin monomer I polymer (FIp) (namely protofibrils). Thrombin can then 
further cleave FpB, making protofibrils assemble laterally into thicker fibrin fibers via αC polymer 
formation (Lord, 2011). Finally, these fibrin fibers connect with activated platelets and participate in 
the formation of the mature web-like fibrin clot with the assistance of coagulation factor XIIIa 
(Chernysh et al., 2012; Elliott et al., 2013). IL-1β may bind directly to the carboxyl-terminal site of the 
γ chain in fibrinogen (Sahni et al., 2003) but its direct contribution to the fiber structure is still unclear. 
In the present study, we used SEM, confocal microscopy, turbidity, and compaction assays to 
demonstrate a direct relationship between IL-1β and the fibrin clot structure. These experiments 
revealed that the addition of 500 pg/mL IL-1β led to a 60% reduction of lag time of protofibril 
formation and also reduced Vmax and maximal turbidity, which resulted in a tighter and thinner fibrin 
clot network. Interestingly, we found no evidence of IL-1β affecting thrombin activity. We think this 
may be due to IL-1β binding with the fibrinogen molecules, thereby promoting the γ-γ crosslinking 
formation between protofibrils; it has been asserted that crosslinking is closely associated with fibrin 
polymerization (Duval et al., 2014; Varadi et al., 1986). In addition, fibroblast growth factor-2 (FGF-2), 
which has a similar β-barrel structure to IL-1β, has been reported to bind to the same residues on the γ 
chain of fibrinogen, such as Phe95, Ser100, Asn102, Arg107, and Arg109 (Peng et al., 2004; Sahni, et 
al., 2004). Further studies are needed to characterize the binding sites that are involved in the 
interactions between IL-1β and fibrinogen. 
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Besides stopping bleeding, the key role of a fracture hematoma is as a defect-filling scaffold situated 
between the proximal and distal ends of the fracture. Not surprisingly, there is in vivo evidence that 
circulating blood cells and fibrin clot formation are closely intertwined and suggest an effect of ‘cell 
surface-related’ factors on clot structure (Lipinski et al., 2012; Undas, 2014). It is quite possible that the 
fibrin network becomes tighter as the distance to the cell surface decreases, since faster rates of 
thrombin formation can be triggered by lipids found on the cell surface (Campbell et al., 2008). 
Therefore, a tightly packed fibrin clot composed of thinner fibers in the larger 3 mm defect would be 
the result of (i) abundant blood cells from ruptured blood vessels and (ii) elevated cytokine levels from 
activated platelets, when compared to the smaller 1 mm defect. This is corroborated by other studies 
that report reduced clot porosity associated with increased levels of inflammatory cytokines (Wang, et 
al., 2016; Wolberg, 2010). Indeed, only a denser fibrin clot with thinner fibers can provide the total 
surface area necessary to achieve adequate haemostasis (Chan et al., 2015; Chan et al., 2016). 
The current paradigm has it that preservation of the hematoma is essential for normal bone repair to 
take place. However, this view has been challenged by a recent study that showed that a persistent 
hematoma without timely fibrinolysis has a detrimental impact on the bone healing process, to the point 
of causing non-unions (Yuasa et al., 2015). Our data would seem to support this notion and prompted 
us to further characterize the initial hematoma. We found a substantial effect deriving from GSNO at a 
concentration of 1 mM, with increased fiber thickness and reduced fiber density in these hematomas. 
There was also a commensurate increase of osteogenesis associated with the GSNO treatment at both 
0.1 and 1 mM, which tapered off at 10 mM. Hematomas are surprisingly complex both in terms of 
biochemistry and structural parameters, such as porosity, the number and property of branch points, 
distances between branch points, and dimension of the pores. This study goes some way towards the 
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goal of developing custom-made hematomas that can act as natural scaffolds with a stabilized clot 
structure to facilitate cell migration and osteogenic differentiation. 
3.5 Conclusion 
In summary, in this study we demonstrate for the first time that the structure of hematomas found in 
delayed healing bone defects were significantly different to hematomas from normal healing bone 
defects. Our data leads us to hypothesise that these differences are directly attributable to increased 
levels of the proinflammatory cytokine IL-1β. Furthermore, pharmacological interventions applied 
directly to the bone defect site, such as the biological agent GSNO, provide an innovative solution to 
delayed bone healing and non-unions. 
  
3.6 Supplementary data 
3.6.1 Altered pro-inflammatory cytokine expression in the hematoma between 1 mm and 3 mm bone 
healing defects 
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Supplementary Figure 3-9: The gene and protein expressions of inflammatory cytokines in hematomas at day 1 in 1 
mm and 3 mm defects. 
(A, B) The IL-1β in hematomas at day 1 showed significant difference in both gene and protein levels between 1 mm and 3 
mm defects; whereas the protein expression of IL-6, IL-10 and TNF-α was little or no difference detected between 1 mm 
and 3 mm defects. NS = no significant difference. P value was obtained by one-way ANOVA test with Holm-Sidak post-
test and represented mean ± SD. n = 6 
 
The gene and protein expressions of the inflammatory cytokines, IL-1β, IL-6, IL-10, and TNF-α were 
investigated in day 1 hematomas from both 1 mm and 3 mm bone defects. mRNA expressions of IL-1β, 
IL-6, and IL-10 was greater in the 3 mm defects compared to the 1 mm defects (P < 0.05), but TNF-α 
was slightly less in the 3 mm defect (Supplementary Figure 3-9A). ELISA of inflammatory cytokines 
revealed high protein expression of IL-1β in the 3 mm defects (745.40 ± 99.19 pg/mL) compared to the 
1 mm defects (57.46 ± 4.72 pg/mL) (P < 0.01). However, there were no significant differences between 
1 and 3 mm defects in the protein expression of IL-6, IL-10, and TNF-α (Supplementary Figure 3-
9B).  
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3.6.2 The effect of IL-1β on clot rigidity 
 
Supplementary Figure 3-10: IL-1β influences blood and fibrin clot rigidity. 
(A, B) The compaction coefficients in blood clots and fibrin clots were significantly higher in the control and 50 pg groups 
compared to the 500 pg group. P value was obtained by One-way ANOVA test with Holm-Sidak post-test. Data was 
presented as mean with SD. n = 5 
 
The percentage of fluid volume from blood clots reached 55.3 % ± 7.3 % and 55.2 % ± 4.6 % in the 
control and 50 pg groups respectively, this compared with 42 % ± 3.1 % in the 500 pg group (P < 0.05) 
(Supplementary Figure 3-10A). We interpreted this as the 500 pg group having a comparatively 
tighter fibrin structure compared to the control and 50 pg groups, since a fibrin clot composed of 
thinner and tighter fibers should have a higher rigidity. In terms of fibrin clots, there was a similar trend 
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in the three groups (61.95 % ± 10.42 % vs 52.78 % ± 2.55 % vs 40.83 % ± 5.07 %) (Supplementary 
Figure 3-10B). The compaction coefficient (%) was inversely correlated to the stiffness of clots. 
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Abstract 
Objectives: Hematoma quality (especially the fibrin matrix) plays an important role in the 
bone healing process. Here, we investigated the effect of interleukin-1 beta (IL-1β) on fibrin 
clot formation from platelet-poor plasma (PPP).  
Methods: Five-milliliter of rat whole-blood samples were collected from the hepatic portal 
vein. All blood samples were firstly standardized via a thrombelastograph (TEG), blood cell 
count, and the measurement of fibrinogen concentration. PPP was prepared by collecting the 
top two-fifths of the plasma after centrifugation under 400 × g for 10 min at 20 °C. The 
effects of IL-1β cytokines on artificial fibrin clot formation from PPP solutions were 
determined by scanning electronic microscopy (SEM), confocal microscopy (CM), turbidity, 
and clot lysis assays.  
Results: The lag time for protofibril formation was markedly shortened in the IL-1β 
treatment groups (243.8 ± 76.85 in the 50 pg/mL of IL-1β and 97.5 ± 19.36 in the 500 pg/mL 
of IL-1β) compared to the control group without IL-1β (543.8 ± 205.8). Maximal turbidity 
was observed in the control group. IL-1β (500 pg/mL) treatment significantly decreased fiber 
diameters resulting in smaller pore sizes and increased density of the fibrin clot structure 
formed from PPP (P < 0.05). The clot lysis assay revealed that 500 pg/mL IL-1β induced a 
lower susceptibility to dissolution due to the formation of thinner and denser fibers.  
Conclusion: IL-1β can significantly influence PPP fibrin clot structure, which may affect the 
early bone healing process.  
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4.1 Introduction 
Fracture hematoma (blood-clot) that is formed immediately after injury is suggested to play 
an important role in fracture union, because the removal of a blood-clot during operative 
stabilization can impair the initial phase of healing (Grundnes et al., 1993). Fracture healing 
is a unique physiologic process characterized by three overlapping stages: fracture hematoma 
formation and the initial inflammatory response, callus formation, and early bony union and 
bone remodeling (Schindeler et al., 2008). Although numerous studies have focused on bone 
biology and fracture healing, to our knowledge, little reported literature is available on early 
bone healing, such as studies characterizing the fracture hematoma fibrin network and the 
factors that impact fibrin clot quality. Hemostasis (blood coagulation) is initiated by platelets; 
however, stabilized fibrin formation throughout hematoma development involves several 
other components, such as immune cells and inflammation cytokines (Kolar et al., 2010; 
Mountziaris et al., 2008). Therefore, the importance of hematoma at a fracture site is 
increasingly being recognized for its supportive role in providing a transient fibrin matrix to 
allow cell infiltration, proliferation, and differentiation, as well as serving as a short-term 
‘reservoir’ for growth factors released from activated platelets and adjacent tissues (Koga et 
al., 2013). 
To better facilitate biocompatibility for bone regeneration, a wide range of autologous blood 
products, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), have been 
employed in a clinical setting (Calori et al., 2008; Saluja et al., 2011; Soffer et al., 2003). 
Indeed, PRP or PRF is a fraction of plasma enriched with activated platelets connected with 
fiber filaments, serving as a functional source of growth factors (Albanese et al., 2013). 
However, the use of PRP to stimulate new bone regeneration has been controversial, owing to 
its rapid release of growth factors from the fibrin network (Hernandez-Fernandez et al., 2013; 
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Plachokova et al., 2007). A more reasonable assumption for PRP not being suitable for bone-
defect healing is its relatively denser fibrin network that impedes the cellular infiltration from 
surrounding tissues (Mosesson et al., 2001; Osathanon et al., 2008). Alternatively, artificial 
fibrin scaffolds with a small pore size, formed by the extensive application thrombin, have 
also been reported to delay natural healing process in a rat model (Karp et al., 2004), 
indicating that fibrin structure alterations (fiber diameter, density,  pore size, porosity, branch 
points, and branch junctions) can considerably influence the bone healing process.  It has 
been revealed that hematomas composed of loosely-woven fibrin structure with thicker fibers 
can better expedite the egress of mesenchymal stem cells (MSCs) and endothelial cells into 
injured sites, diffusion of oxygen and nutrients, and removal of metabolic waste (Collen et al., 
1998; Willie et al., 2010). 
Acute phase response (APR) is the earliest response to vascular injury at fracture sites, 
characterized by the generation of acute phase proteins, such as fibrinogen and cytokines 
(Aggrey et al., 2013). After vascular compromise, activation of blood coagulation occurs 
quickly when whole blood interacts with the surface of broken bone fragments. The 
adsorption of plasma proteins is deemed to initiate platelet reaction and an extrinsic 
coagulation cascade, resulting in thrombin enzyme and fibrin formation, and finally a 
hematoma at the fracture sites (Claes et al., 2012). Currently, a growing body of evidence 
indicates that inflammation and hematoma formation are closely intertwined (Kolar, et al., 
2010; Mountziaris, et al., 2008). It has been demonstrated that IL-1β, a major inflammatory 
cytokine released from activated platelets and immune cells, can bind to fibrinogen thus 
preserving its activity (Sahni et al., 2004), but its impacts on fibrin clot structure has garnered 
little attention. Notably, the expression of IL-1 beta, especially with the simulation of 
lipopolysaccharides (LPS), has been documented in early bone fracture healing (day 3) 
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(Einhorn et al., 1995). Studies with mice tibial fractures showed that the local administration 
of IL-1β exerted an inhibitory effect on proliferation of MSCs (Lange et al., 2010), and IL-1β 
antagonist can facilitate fracture restoration in rat model (Perrien et al., 2004). While most 
investigators used the dose of IL-1β ranging from 10 pg/mL to 1000 pg/mL (Hengartner et al., 
2013), our recent study (unpublished data) also revealed that the levels of IL-1β were 
significantly higher in delayed bone healing defects (745.40 ± 99.19 pg/mL) than ones in 
normal bone healing defects (57.46 ± 4.72 pg/mL). Therefore, we selected 50 and 500 pg/mL 
as experimental concentrations to observe whether IL-1β is a major determinant of altering 
clot construct, thus influencing the healing process of large bone defects. 
PPP is the supernatant of plasma with low amounts of platelets and blood cells, which 
contains elevated levels of fibrinogen to generate a non-turbid fibrin-rich clot once activated 
(Stevic et al., 2013). Moreover, fibrin clot formed from PPP could be used as an autologous 
degradable scaffold for tissue engineering (Hatakeyama et al., 2014). Exempt from 
disturbances of other blood plasma components (platelets and blood cells), PPP on behalf of 
whole blood is often used to investigate the inherent architecture of fibrin clots (Bateman et 
al., 2012; Gersh et al., 2009). Therefore, this study aimed to determine whether IL-1β could 
influence the fibrin structural properties in PPP clots. 
 
4.2 Materials and Methods 
4.2.1 Reagents 
Human Alpha Thrombin (HT 1002a) and human plasminogen (HPg 2001) were acquired 
from the Enzyme Research laboratories (Bulimba, Australia). Human Fibrinogen (Oregon 
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Green™ 488 Conjugate) and Interleukin-1β were purchased from Invitrogen (Victoria, 
Australia). Recombinant tissue-type plasminogen activator and D-Dimer (D2D) ELISA Kit 
were ordered from antibodies-online Inc. (Atlanta, United States). 
 
4.2.2 Standardization of blood sampling 
Blood was preserved by collecting 900 µL of blood from the hepatic portal vein of Fisher rats 
in 100 µL of 4% tri-sodium citrate (9:1). Blood samples were mildly inverted 6 times, and 
kept upright for at least 30 min. For the TEG test, 320 µL of blood was transferred gently into 
a disposable plastic TEG cup (Haemoscope Corporation) containing 20 µL of 0.2 M CaCl2 
solution, and the assay was performed on a TEG® 5000 Series Haemostasis Analyser at 37 °C 
within 1 h of blood collection. The parameters were automatically traced with TEG, 
including reaction time (R, seconds), coagulation time (K, seconds), angle (α, degrees), and 
maximum amplitude (MA, mm). Details of this method are described in a previous report 
(Wohlauer et al., 2011). 
Two-hundred microliters of citrated rat whole blood volume was analyzed with the 
Haematology Analyser (XT-2000i) to measure red blood cell (erythrocyte), white blood cell 
(leukocyte), and platelet populations. Additionally, 2 mL of citrated blood volume was 
centrifuged at 10,000 rpm (1300 × g) for 15 min at room temperature. Then, a 100 µL aliquot 
of the supernatant was transferred to a 1.5 mL plastic tube for analysis using the ACL TOP 
CTS Haemostasis Analyser, which detected the fibrinogen concentration in the plasma.  
 
4.2.3 PPP preparation 
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PPP was prepared according to previously published protocols (Naik et al., 2013; Saluja, et 
al., 2011). Briefly, 5 mL of blood drawn from hepatic portal vein were added to 15 mL 
Falcon tubes. The fresh blood samples were immediately transferred into a centrifuge. After 
the centrifugation at 3000 rpm (400 × g) for 10 min at 20 °C, the mixture was divided into 
three layers: the upper layer was acellular plasma (PPP), the lower layer was red blood cells 
(RBC), and the middle layer was a buffy coat layer (PRF) that was rich in platelets and had a 
paucity of leucocytes. PPP was completely decanted and stored at -80 °C. Fibrinogen 
concentration in PPP solutions was measured by the ACL TOP CTS Haemostasis Analyser 
and 1 mg/mL was used in this study.  
 
4.2.4 Turbidity 
Fibrin polymerization in PPP clots was monitored in a 96-Well MicroWell Plate (Thermo 
Scientific, USA) by tracing alterations in turbidity at 405 nm (A405) every 15 s for 50 min, at 
37 °C using a Microplate Absorbance Reader (Bio-Rad X-Mark spectrophotometer) as 
described previously (Konings et al., 2011; Zucker et al., 2014). The 100 µL PPP solution (1 
mg/mL) with IL-1β (0, 50, or 500 pg/mL) in HEPES buffer (20 mM HEPES, 150 mM Nacl, 
pH = 7.4) was preincubated for 10 min at 37°C. The PPP solution mixed with only HEPES 
buffer instead of IL-1β was defined as the control. Additionally, thrombin (0.1 U/mL) and 
CaCl2 (10 mM) were blended and preincubated for 10 min at 37 °C. The lag time represented 
the rate of protofibril formation and the size and number of fibers were typified by the 
maximal turbidity.  
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4.2.5 Scanning electron microscopy (SEM) 
SEM studies for blood clot characterization were carried out as described previously (Lai et 
al., 2010; Shiu et al., 2014) with the following minor modifications. PPP clots were formed 
by the PPP (1 mg/mL) with IL-1β (0, 50, or 500 pg/mL), thrombin (1 U/mL), and CaCl2 (10 
mM) in HEPES buffer. The PPP solution in HEPES buffer without IL-1β mixed with 
thrombin and CaCl2 was defined as the control. After 2 h at room temperature, clots were 
rinsed with phosphate buffer saline (PBS) (pH = 7.4) at least 3 times, and then fixed in 3 % 
glutaraldehyde overnight. Thereafter, clots were transferred to a cacodylate buffer (0.1 M), 
post-fixed with 4% osmium, and dehydrated with an ethanol gradient. Specimens were 
mounted on carbon tabs, and sputter coated with gold-palladium. All specimens were 
analysed under a Zeiss SEM (FEI, USA) at a magnification of 10,000 ×, which could detect 
an individual fiber. Fiber structural parameters (thickness and density) were further measured 
using the Image J software (version 1.43) according to a modified method of Undas et al 
(Undas et al., 2008). For quantitative analysis of the pore sizes in fibrin clots, the 
thresholding algorithm (0, 60) was run to highlight the black areas (no fibers). The black 
(space) portions of the images were quantified and defined as 2-D percentage porosity. Pore 
area was obtained using the performing particle analysis function in Image J (Li et al., 1998; 
Textor et al., 2014). 
 
4.2.6 Confocal microscopy (CM) 
PPP solutions (100 µL, 1 mg/mL) with IL-1β (0, 50, or 500 pg/mL) in HEPES buffer was 
coupled to the Oregon Green™488 fibrinogen (0.1 mg/mL) on the coverslips (Thuringowa, 
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Australia). After the addition of thrombin (1 U/mL) and CaCl2 (10 mM), PPP clots were 
formed in a moist atmosphere at room temperature overnight. Clots were prepared for 
observation using a Nikon A1R Confocal Microscope with a 40 × 1.3 NA oil objective as 
described previously (Collet et al., 2000; Konings, et al., 2011) with following modifications. 
The scans were taken using the 6 × zoom-in mode. After acquisition of PPP clot 
morphological images, maximum intensity projections (MIP) images were analyzed. Fiber 
size was measured by drawing a perpendicular line across the fiber, avoiding any junctions. 
Moreover, the fiber density was counted by drawing a 50-µm line across the middle 
transections of the scanned MIP image. The representative morphologies of fibrin clot were 
captured. 
 
4.2.7 Clot lysis assay 
Clot lysis is strongly correlated with fiber thickness and density. The eﬀect of various 
concentrations of IL-1β on overall clot degradability was evaluated and its association with 
the fibrin architecture was investigated. The fibrinolytic process was evaluated by detecting 
the amounts of fibrin degradation product (D-dimer) when the fibrin clots were dissolved by 
the plasmin, which yielded activation of plasminogen in the presence of tissue-type 
plasminogen activator. 
A suspended clot system was applied in this study as described previously (Shiu, et al., 2014; 
Viennet et al., 2014). PPP solutions (100 µL, 1 mg/mL) with IL-1β (0, 50, or 500 pg/mL) in 
HEPES buffer, thrombin (1 U/mL), and CaCl2 (10 mM), were simultaneously added to the 
vials for 2 h at 37 °C to allow complete clot formation. Clots were transferred into the new 
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vials and suspended in 3 mL of PBS buffer containing human plasminogen (Glu-plasminogen, 
5.4 μg/mL final concentration; American antibodies-online Inc., USA). The clot lysis process 
was initiated by adding tissue plasminogen activator (tPA, 0.25 μg/mL final concentration; 
Australia Enzyme Research laboratories Inc., AU) at 37 °C with gentle agitation. Aliquots of 
the supernatant (100 μL) were pipetted at timed intervals (1, 4, 8, 18, and 24 h) and 
centrifuged at 1000× g for 3 min for D-dimer detection. The extent of clot lysis was detected 
by measuring the amounts of D-dimer by use of a D-dimer ELISA kit (American antibodies-
online Inc., USA). In addition, weight losses of clots were also recorded at the indicated time 
points. 
 
4.2.8 Ethics statement 
Ethic approval was granted for this study from Queensland University of Technology 
(approval number: 1400000023). 
 
4.2.9 Statistical analyses 
Results were represented as the means ± standard derivation. For statistical evaluation, 
Student’s t-test was used for two group differences and one-way analysis of variance 
(ANOVA) was used for three group differences, followed by post-hoc test. A p value <0.05 
was considered statistically significant. 
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4.3 Results 
4.3.1 Standardization of blood collection using hematological parameters by the analysis of 
TEG, Haematology, and Haemostasis Analyser 
 
Figure 4-1: Profile of TEG parameters, blood cell count, and fibrinogen concentration. 
(A, B) This profile comprised two processes, namely, thrombosis and fibrinolysis. Thrombosis was described by 
four important parameters: R time; which was calculated from the time that the blood was pipetted into the TEG 
analyzer till initial fibrin clot formation. K time was the time at which clot formation reached amplitude of 20 
mm, representing clot formation speed. In addition, α angle denoted the level of fibrinogen. MA value was a 
reflection of platelet function and aggregation, which indicated that clot strength (stiffness) reached the 
maximum amplitude.  
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From panel A in Figure 4-1, the TEG parameters from the collected blood were detailed as 
follows: mean reaction time (R, 548.3 ± 95.09, s), mean coagulation time (K, 233.8 ± 52.27, 
s), angle value (α, 45.8 ± 6.71, degrees), and mean maximum amplitude (MA, 63.3 ± 5.9, 
mm). In panel B and C, the outcomes of hematology parameters were consistent with the 
described literature using Haematology and Haemostasis Analyser measurements (Mackie et 
al., 2003; River, 1984; Wohlauer, et al., 2011). The performance of TEG was aimed to 
standardize the constituents of whole blood within the biological range, which minimized 
blood sample variation between individuals and ensures that PPP solution made from whole 
blood was at an identical level. 
 
4.3.2 Fibrin polymerization 
 
Figure 4-2: The effect of IL-1β on fibrin polymerization of PPP clots. 
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Effect of IL-1β on polymerization of PPP clots (A, D, E) and effect of different concentrations of thrombin on 
PPP clots (B, C). In figure B and C show the lag time when turbidity absorbance starts to rise to 0.001 and 
maximal turbidity in PPP solutions with thrombin (0.01, 0.02, 0.04, 0.1 or 0.5 U/mL) and CaCl2 (10 mM) in 
HEPES buffer (pH =7.4). In figure A, fibrin polymerization was plotted using three different colors: dark 
(control group), dark gray (50 pg/mL IL-1β group), and light gray (500 pg/mL IL-1β group). Figure D and E 
represent lag time and maximal turbidity in PPP solutions by addition of thrombin (0.1 U/mL) and CaCl2 (10 
mM), respectively. Data from 5 replicates were analyzed by unpaired Student t-tests. NS indicated no significant 
differences. 
 
Figure 4-2 showed that variations of thrombin concentration (more than 0.1 U/mL) can 
significantly affect lag time and maximal turbidity during PPP clot polymerization process 
compared with control (0.01 U/mL) (P < 0.01) (B, C), suggesting that clot kinetics (lag time 
and maximal turbidity) were inversely proportional to increases in thrombin concentrations. 
Furthermore, the dynamic of ﬁbrin polymerization in PPP solutions was characterized by 
measurement of turbidity curves by the addition of thrombin (0.1 U/mL) and CaCl2 (10 mM) 
with or without IL-1β (A). Lag time was detected from the turbidity curve to be 543.8 ± 
205.8 s in control groups, which was significantly longer than the IL-1β groups (D) (243.8 ± 
76.85 s in the 50 pg/mL and 97.5 ± 19.36 s in the 500 pg/mL) (P < 0.01). Maximal turbidity, 
the final optical density, was determined from the turbidity curve to be 0.0778 ± 0.0052 in 
control group, while it was 0.0773 ± 0.001 in the 50 pg/mL groups and 0.0683 ± 0.0023 in 
the 500 pg/mL groups (E) (P < 0.05). 
 
4.3.3 Fibrin architecture 
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Figure 4-3: The effect of IL-1β on fibrin architecture of PPP clots. 
Morphology of PPP clots (n = 3) architecture (A, B, C) formed by different concentrations of IL-1β were 
analyzed using Zeiss SEM. Fiber diameter (D) (n = 150), density (E), and pore size (F) were measured using the 
Image J software. Fibers appear significantly different in the IL-1β groups at the concentration of 500 pg/mL 
with a thinner diameter, denser, and lower porosity (scale bar = 2 µm). 
 
As evident from the graphs shown in Figure 4-3, PPP clots formed in the absence of IL-1β 
(A) or in the presence of IL-1β (B, C) revealed a multitude of individual fibers in the fibrin 
networks. The mean diameters of fibers in PPP clots were 192.6 ± 46.84 nm in the control 
groups, and 181.6 ± 47.40 nm in the 50 pg/mL IL-1β groups (D). Fiber diameters decreased 
dramatically in the 500 pg/mL IL-1β treatment group with fiber diameters ranging 74.70 ± 
14.27 nm (D) (P<0.01). In contrast, there was a higher density of fibers in the 500 pg/mLIL-
1β groups (19.50 ± 2.22) compared to the other groups (E) (11.00 ± 2.26 and 11.30 ± 1.70 in 
the control groups and 50 pg/mL IL-1β groups, respectively). Mean pore areas of 500 pg/mL 
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IL-1β group were significantly (P<0.05) smaller (range, 4.053 to 4.289 µm2) than that of the 
control groups (range, 5.219 to 6.787 µm2) and the 50 pg/mL IL-1β groups (range, 4.854 to 
6.172 µm2) (F). 
 
4.3.4 Fibrin clot structure 
 
Figure 4-4:  The effect of IL-1β on fibrin clot structure of PPP clots. 
Structural morphology of PPP clots formed by 500 pg/mL IL-1β (n = 3) (A, C). In 0, 50, 500 pg/mL 
IL-1β groups, using the function of Annotations and Measurements, fiber diameters were determined 
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from maximum intensity projections (MIP) (B). Fiber densities were counted in the Intensity graph 
obtained by calculating the peaks (the number of fibers) that cross a line of 50 µm (D). Scale bars 
represent 10 µm. 
 
The results in Figure 4-4 indicated that the denser fibrin structure with thinner fibers was 
formed in the 500 pg/mL IL-1β groups. The oversaturated color and noise were minimized by 
the application of look-up tables (LUTs), and, consequently, the measurements of fiber 
parameters would be more reliable. Fiber diameters were 671.4 ± 93.71 nm in the control 
groups and 605.7 ± 100.8 nm in the 50 pg/mL IL-1β groups. However, fiber widths were 
merely 448.6 ± 57.57 nm in the 500 pg/mL IL-1β groups. Using the Intensity Profile and 
Object Count tools, the amounts of fibers were found to be 12.00 ± 2.45,14.20 ± 2.59,20.20 ± 
1.92 in the 0, 50, and 500 pg/mL IL-1β groups, respectively. 
 
4.3.5 Fibrinolytic assay 
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Figure 4-5: The effect of IL-1β on fibrinolytic activity of PPP clots. 
A PPP clot formed by the addition of thrombin (1 U/mL) and CaCl2 (10 mM) for 2 h at 37 °C (A), after 18 h of 
lysis, the size of the clot showed a notable decrease (B). Releases of D-dimer and weight loss were measured 
during PPP clot lysis over 24 h (C, D). The D-dimer levels of clots formed by various concentrations of IL-1β 
(C) and the percentage of weight losses denoting the lysis of clots (D). * P ≤ 0.05, **P ≤ 0.01 
 
To evaluate the effect of various concentrations of IL-1β on fibrinolysis, D-dimer levels and 
weigh losses from the clots were compared in one-way ANOVA (Figure 4-5). At 1 h, all 
clots revealed significant increase of D-dimer, reflecting the fibrinolytic activity has 
commenced. The 50 pg/mL IL-1β groups initially underwent a relatively slower rate of 
fibrinolysis (P < 0.05). However, no significant differences were found at the following 4 and 
8 h. At 18 and 24 h, the concentrations of D-dimer rapidly increased in the control groups 
compared to IL-1β groups, suggesting that fibrin fibers in the control group were subjected to 
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dissolution. This was also in line with the outcomes from weight losses among the three 
groups. 
 
4.4 Discussion 
The prevalence of complications from bone fracture treatments for large bone defects, such as 
delayed bone union and bony non-union, continue to be clinical challenges. Although an 
accumulating number of traditional approaches, such as bone substitutes, have been 
introduced in implantology, the use of these therapies is often unpredictable and complicated 
with potential safety issues, such as a foreign body reaction, which leads to fibrotic 
encapsulation and implant dysfunction (Ghanaati et al., 2013; Morais et al., 2010). When 
vascular injury occurs at a fracture site, platelets and the fibrin-producing clotting system, 
which mediate hemostasis, produce a functional fracture hematoma that seals the bone 
broken fragments and re-constructs vascular continuity (Echeverri et al., 2015). While 
platelet aggregation provides temporary closure of the defect, the initiation of a multistep 
coagulation reaction in a highly efficient manner ensures that it remains mechanically stable 
via generation of the glue-like fibrin within a growing fracture hematoma (Furie et al., 2008). 
Parallel with the recruitment of platelets, a large number of platelet-related molecules, such 
as, fibrinogen, growth factors, and pro-inflammatory cytokines, are produced or activated, 
thereby participating in fibrin generation (Morrell et al., 2014). During the dynamic process 
of fibrin polymerization, the concomitant activation of blood coagulation and inflammation 
has been suggested to be closely linked (Von Bruhl et al., 2012). It is well-known that the 
fibrin structure determines cell migration and proliferation during the healing process.   
In this study, in order to maintain consistency among blood samples collected from rats, all 
samples were first subjected to standardization using the TEG, Haematology, and 
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Haemostasis Analyser. By means of the formulation of artificial PPP clots in vitro, we 
observed from turbidity measurements that the lag time (97.5 ± 19.36 s) in the 500 pg/mL IL-
1β group was markedly shortened compared with the control groups (543.8 ± 205.8 s; P < 
0.01). This indicated that the single application of IL-1β (500 pg/mL) can yield the formation 
of PPP clots with high density of fibers, possibly owing to expedition of the γ-γ crosslinking 
between protofibrils (Duval et al., 2014). Accordingly, there was a remarkable decrease in 
maximal turbidity in the 500 pg/mL IL-1β groups, implying that the fiber size became thinner 
than the control groups (P < 0.05). Furthermore, morphological parameters of the fibrin fiber 
(diameter and density) were characterized using SEM and CM, which implied that IL-1β 
(500 pg/mL) with thrombin could dramatically alter the structural properties of artificial 
fibrin clots (P < 0.01). IL-1β affects fiber size, possibly by directly affecting the carboxyl-
terminal site of the γ chain in fibrinogen (Sahni et al., 2003), which has a close relation to the 
γ-γ crosslinking in fibrin polymerization (Duval, et al., 2014; Varadi et al., 1986). 
Clot fibrinolytic activity using a suspended clot system revealed that the IL-1β groups 
initially experienced a relatively slower rate of fibrinolysis according to the detection of D-
dimer amounts and weight loss. At 18 h of clot lysis, the D-dimer concentration significantly 
increased in the control groups compared to IL-1β groups, which was in accordance with the 
loose and thicker clot network observed in the control groups under SEM and CM. This is 
further evidenced by the literature, which shows that fibrinolysis occurs much faster on a 
loose and thicker fibrin network rather than on a tight and thinner one (Longstaff et al., 2013; 
Lord, 2011). 
The main limitation of this study is that a PPP clot does not completely stand for a whole 
blood clot (hematomas). However, the advantage of using PPP is that exposure of individual 
in the clots fibrin fiber becomes evident for characterization under observations of SEM and 
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CM. Currently, to our best knowledge, few literature reporting how to detect and measure 
fibrin parameters of whole blood clots under CM. Given that thrombin produced by 
remaining platelets in PPP solutions is insufficient to initiate coagulation cascade, addition of 
exogenous thrombin is requisite for PPP clot formation as described by Gersh et al (Gersh, et 
al., 2009) and Talens et al (Talens et al., 2012). 
Fracture hematoma is widely believed to be a biologically active tissue where thrombin, the 
major end product of the coagulation cascade, is activated in the event of an injury to 
hemostasis. In addition, a diverse subset of other cellular and molecular elements including 
proinflammatory cytokines is also recognized as being essential to exploit their procoagulant 
repertoire, thereby propagating coagulation (Engelmann et al., 2013). The clarification of 
specific underlying relationship between proinflammatory cytokines, such as IL-1β and fiber 
structure, in this study expands our understanding of its thrombogenesis, and should 
consequently facilitate development of a novel strategy for treatment of large bone defect via 
alteration of fiber structures in hematomas.  
 
4.5 Conclusion 
In summary, this study confirmed that by simply varying the IL-1β concentration in a PPP 
solution, the lag time of protofibril formation and maximum turbidity without additional 
fibrinogen or thrombin can be significantly reduced. Therefore, controlling proinflammatory 
cytokines such as IL-1β concentration may present a novel intervention for tailoring fibrin 
clot architecture to improve the repair and regeneration of skeletal tissues. 
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Abstract 
 
The quality of hematoma is crucial for successful early bone defect healing, as the structure 
of a fibrin clot significantly influences the infiltration of cells from adjacent tissues into the 
fibrin network to regenerate bone. Previous studies have demonstrated that interleukin-1β 
(IL-1β) can influence clot polymerization and structural properties using purified fibrinogen 
solution and rat platelet poor plasma (PPP); however, influence of IL-1β on fibrin clot 
architecture in whole blood remains unclear. This study is to investigate the impact of IL-1β 
on the fibrin structure of whole blood clot. The effects of IL-1β on the structural properties of 
whole blood clots were evaluated by thrombelastograph (TEG), scanning electronic 
microscopy (SEM), compressive study, and thrombolytic assays. This study demonstrated 
that IL-1β can lesser affect the clot architecture in whole blood compared to PPP clots but 
still reached a significance, which  may have a pivotal role in early bone healing. 
 
 
 
Key words: Blood coagulation, fibrin, hematoma, interleukin-1 beta, wound healing 
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5.1 Introduction 
Fracture hematomas (blood clot) are fibrin scaffolds that are produced immediately following 
a bone injury and are considered a vital element in fracture healing. To date, autologous 
platelet concentrates, such as platelet-rich plasma (PRP) have been trialled as potential 
bioactive materials to enhance bone regeneration. It was thought that these treatments would 
provide a fibrin matrix that could act as a reservoir that could release a consistent flow of 
growth factors (Bielecki et al., 2012). However, there are studies casting doubts on the 
efficacy of PRP since these treatments showed little evidence of accelerating the bone repair 
process in either animals or humans (Jensen et al., 2005; Peerbooms et al., 2012). One 
explanation for this lack of efficacy is the significantly denser fibrin meshwork found in PRP, 
which is supposed to be due to the supra-physiological levels of thrombin used. The dense 
fibrin clot decreases permeability and significantly retards cellular migration from adjacent 
tissues (Khiste et al., 2013). Such artificial ex vivo fibrin scaffolds have smaller pore sizes 
and been shown to slow bone healing in rats (Karp et al., 2004). By contrast, porous fibrin 
clots composed of thicker fibers has been shown to promote migration of endothelial cells 
and enhance ossification within injured sites (Collen et al., 1998). This indicates that 
variations in fibrin structure properties (such as pore size) can considerably modulate cell 
infiltration and wound healing process. 
 
There is ample evidence to suggest that the inflammatory reactions can promote a 
prothrombotic state and initiate thrombogenesis (Vergouwen et al., 2008). At fracture sites, 
the chemotaxic effect of IL-1β on mesenchymal stem cells has been implicated as a main 
trigger contributing to early healing within a day of a fracture (Kon et al., 2001). Although 
IL-1β has been reported to bind directly to fibrinogen (Sahni et al., 2004), to date no studies 
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have demonstrated its direct effects on fibrin structure during hemostasis. In the previous 
studies of this thesis it has demonstrated that interleukin-1β (IL-1β) can influence clot 
polymerization and structural properties using purified fibrinogen solution and rat platelet 
poor plasma (PPP); however, whole blood contains a number of blood cells and platelets. 
Therefore, the influence of IL-1β on fibrin clot architecture in whole blood remains unclear. 
In the part of study it was investigated whether IL-1β exerted a regulatory role on fibrin 
polymerization and hematoma structure in whole blood.  
 
5.2 Materials and methods 
5.2.1 Reagents 
Human Alpha Thrombin (HT 1002a) and human plasminogen (HPg 2001) were acquired 
from Enzyme Research Laboratories (Bulimba, Australia). Human Interleukin-1β was 
purchased from Invitrogen Thermo Fisher Scientific Inc (Victoria, Australia). Recombinant 
human tissue-type plasminogen activator (t-PA) and D-dimer (D2D) ELISA Kit were 
purchased from Antibodies-Online Inc. (Atlanta, USA).  
 
5.2.2 Blood samples 
Human whole blood samples were sourced from the Australian Red Cross Blood Bank. The 
plasma fibrinogen concentrations measured by the Clauss method ranged from 2 to 2.5 g/L 
(Clauss, 1957). All blood samples were collected from healthy donors who had no history of 
coagulation disorders or had taken any haematological related medication in the preceding 6 
months. Ethical approval (1500000918) was granted by the University Human Research 
Ethics Committee (UHREC) at Queensland University of Technology. 
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5.2.3 Thromboelastography (TEG)  
Thromboelastography was performed using a TEG® 5000 Series Hemostasis Analyser 
System (Hemoscope Corporation, Niles, IL) to measure the viscoelastic properties of citrated 
whole blood clots. Three-hundred and twenty microliters of human blood were pipetted into 
oscillating plastic TEG cups and the coagulation process was re-calcified by the addition of 
20 µL of 0.2 M calcium chloride (CaCl2) solution with or without HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) buffered IL-1β (50 or 500 pg/mL). The 
profile of clot formation was traced using the TEG5000 Series Hemostasis System for 1.5 h 
at 37°C. The hemostatic parameters, such as split point (SP), reaction time (R-time), 
coagulation time (K-time), alpha angle (α), and maximum amplitude (MA), were recorded 
and analysed. SP reflects the initial fibrin formation, R time measures the initial clot 
formation time, both K time and α angle are direct indicators of thrombosis formation speed, 
and MA is indicative of the maximal strength of the clots (Elnager et al., 2015; Lai et al., 
2014). The procedure was repeated three times. 
 
5.2.4 Scanning electron microscopy  
Blood clots were prepared from 100 µL of whole blood with 10 µL of 0.2 M CaCl2 with and 
without IL-1β (50 or 500 pg/mL). These mixtures were incubated at 37°C for 2 h to allow 
clotting to proceed and then fixed in 3 % glutaraldehyde overnight. The resulting clots were 
rinsed with PBS at least 3 times and dehydrated in an ascending alcohol series (50 %, 70 %, 
90 %, and 100 %) and dried in a CO2 critical point drying apparatus. The specimens were 
then mounted on aluminium stubs and coated with gold-palladium, and micrographs captured 
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by SEM (FEI, USA). Representative images were captured at 5,000× magnification and the 
images analysed using a method described previously (Neergaard-Petersen et al., 2013; 
Undas et al., 2008). Fiber thickness and density were assessed from SEM images using image 
analysis software package Image J (version 1.43). Fiber diameter (n = 90) from each 
concentration was analysed and reported as an average. Three images were analysed from 
each clot sample and data were acquired from each of the three clots from each concentration. 
 
5.2.5 Compressive moduli 
Blood clot stiffness was quantiﬁed with an Instron 5848 Microtester (Canton, MA) using the 
method established by Davis et al and Textor et al (Davis et al., 2011; Textor et al., 2014). 
Blood clots with or without IL-1β (50 or 500 pg/mL) were allowed to polymerize in a 24-
well plate for 24 h at 37°C. The length and diameter of the blood clots were recorded and 
clots incubated in PBS for 1 h prior to stiffness measurements taken. Blood clots were loaded 
on a ﬂat plate and compressed at 10 mm/min with a preload of 5 N with an extension limit of 
3.5 mm. The linear region of force-displacement curve was determined within strain ranging 
from 0 to 5 %, and the slope was defined as Young’s modulus (compressive stiffness), which 
were calculated using equations 1, 2, and 3. The experiment was repeated three times. 
Equation ①: Stress (Pa) =
Compressive force 
Compression area
 
Equation ②: Strain (%) =
Deformation length 
Original length
 
Equation ③: Young′s modulus (Pa) =
Stress 
Strain
 
 
5.2.6 Thrombolytic assay 
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The thrombolytic activities of whole blood clots were assessed in a suspended clot system 
using the method detailed by Shiu et al (Shiu et al., 2014). Hundred microliters of 0.2 M 
CaCl2 with or without IL-1β (50 or 500 pg/mL) was added to 1 mL whole blood and 
incubated for 2 h at 37°C. Once the blood clotted, the clots were transferred into new vials 
containing a final concentration of 5.4 μg/mL human Glu-plasminogen in 3 mL of PBS 
buffer suspension. The thrombolytic reaction of the clots was activated by addition of 0.25 
μg/mL tissue plasminogen activator (t-PA) and agitated gently at 37°C. Aliquots were 
removed at nominated time points (1, 4, 8, 18, and 24 h) and spun at 1000 × g for 3 min. 
Supernatants (100 μL) were assayed using a D-dimer ELISA kit (Antibodies-Online Inc., 
USA). The quantity of D-dimer, released from the clots, reflected the thrombolytic activity of 
the samples. Additionally, fibrinolysis was measured in whole blood clots in PBS without t-
PA to account for spontaneous fibrinolysis and was defined as controls. The weight of clotted 
bloods was also recorded at 0, 18, and 24 h to assess clot weight change. The experiment was 
repeated three times for each concentration. 
 
5.2.7 Statistical analyses 
Data from all the experiments were expressed as averages plus and minus standard deviation 
(SD). Statistical differences were assessed between two groups using unpaired two-tailed 
Student t-tests. A one-way analysis of variance (ANOVA) with Holm-Sidak’s tests was 
performed from GraphPad Prism 6.0 for multiple comparisons. A p value of less than 0.05 
was determined as a significant difference. 
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5.3 Results 
5.3.1 IL-1β influences clot kinetic of human blood clots 
 
Figure 5-1: IL-1β influences thrombosis process of human blood clots. 
(A) Diagrammatic representation of a standard TEG profile demonstrating the generally described variables: SP, 
split point; R, reaction time; K, coagulation time; α angle; MA, maximum amplitude. (B) Representative TEG 
traces of human whole blood clots treated with 0, 50, 500 pg/mL concentrations of IL-1β (n = 3). (C) Effects of 
different concentrations of IL-1β on TEG parameters of human whole blood clots.  (n = 3, NS indicated no 
significant difference). 
 
Hemostatic parameters, such as SP, R-time, K-time, alpha angle (α), and MA, were assessed 
using a TEG analyser. Initial fibrin formation time, reflected by SP and R, was significantly 
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shorter in the 500 pg/mL IL-1β group compared to the control group (SP, 198.3 ± 7.6 vs. 
340.0 ± 35.0, s; R time, 371.7 ±11.6 vs. 446.7 ± 20.8, s) (Figure 5-1). Thrombosis formation 
speed is expressed by both K time and α angle, while MA is a measure of the maximal 
strength of the clots. The K value was significantly shorter in the 500 pg/mL IL-1β group 
compared to the controls (K, 110.0 ± 15.0 vs. 198.3 ± 36.2, s), whereas the α angle and clot 
strength (MA values) of the whole blood clots increased noticeably in the 500 pg/mL IL-1β 
group compared with the control group (α, 59.1 ± 0.7 vs. 50.2 ± 1.9, degree; MA, 64.9 ± 3.1 
vs. 57.0 ± 2.0, mm) (Figure 5-1).  
 
5.3.2 IL-1β influences fibrin clot structure of human blood clots 
 
Figure 5-2: IL-1β influences fibrin construct of human blood clots. 
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Scanning electron micrographs of blood clot networks in presence of formed by 0 (A), 50 (B), 500 (C) pg/mL 
IL-1β (scale bar = 5 µm, n = 3).  Average diameter of fibers (n = 90) (D) and average density of fibers (E) were 
calculated using Image J software. E = erythrocytes, L = leukocytes, and PL = platelets. 
 
Structural analysis of blood clots formed with or without IL-1β by SEM showed there was a 
significant difference in fiber thickness between the IL-1β and control group (Figure 5-2A-
C). In the 50 and 500 pg/mL IL-1β treatment groups, the clots exhibited significantly thinner 
fibers (385.6 ± 67.0 nm and 228.8 ± 35.4 nm in, respectively) compared to the controls 
(470.4 ± 124.7 nm) (p < 0.05) (Figure 5-2D). Clots formed in the presence of 500 pg/mL IL-
1β exhibited a higher density of fibers (26.8 ± 3.7 fiber per 30 µm2) than the controls (9.0 ± 
2.9 fiber per 30 µm2) (p < 0.05) (Figure 5-2E). The fibrin networks in the 500 pg/mL IL-1β 
group had discernibly thinner and more densely packed fibers compared to the control group 
(Figure 5-2). 
 
5.3.3 IL-1β influences biomechanical property of human blood clots 
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Figure 5-3: IL-1β influences biomechanical property of human blood clots. 
Influence of IL-1β on the mechanical properties of whole blood clots (n = 3). (A) Representative stress-strain 
curves plotted from compressive test on whole blood clots formed in the presence of 0, 50, 500 pg/mL of IL-1β. 
(B, C) Young’s modulus was measured by calculating the slope in the initial linear proportion (0 - 5 %) (n = 3) 
(see Methods and Materials). In addition, the Young’s modulus is not a constant but increase as the clot 
responds to compression, this phase is defined as strain hardening (non-linear proportion) owing to fibrin 
meshwork deformation of blood clots. 
 
Mechanical testing in the form of compression analysis evaluated the eﬀect of IL-1β on 
mechanical properties of whole blood clot formation with (50 or 500 pg/mL) and without 
(control) IL-1β (Figure 5-3A-C). There was no statistically signiﬁcant diﬀerence in Young’s 
moduli between the control group (0.47 ± 0.12 kPa) and 50 pg/mL IL-1β group (0.57 ± 0.12 
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kPa) (p > 0.05). However, the Young’s modulus of the 500 pg/mL IL-1β treatment group at 
0.87 ± 0.15 kPa was significantly higher than the controls (p < 0.01). 
 
5.3.4 IL-1β influences the susceptibility of human blood clots to thrombolysis 
 
Figure 5-4: IL-1β influences the susceptibility of human blood clots to thrombolysis. 
Photographs of thrombolysis of whole blood clots incubated with CaCl2 with or without IL-1β for 2 h followed 
by addition of t-PA for 24 h (n = 3) (A). Effect of IL-1β on D-dimer concentration in thrombolytic blood clots (n 
= 3) (B). Effect of IL-1β on percentage of weight loss in thrombolytic blood clots (n = 3) (C). In panel A, 
significantly visual changes occurred between four groups, indicating that the weight losses of clots from IL-1β 
treatment groups (50 and 500 pg/mL) were less than that of the control group (0 pg/mL) (n = 3). * p ≤ 0.05, **p 
≤ 0.01 
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Thrombolytic activity in fibrin clot construct with or without IL-1β was investigated by 
measuring the amount of D-dimer (Figure 5-4A-C). We found there were significantly visual 
variations amongst the four groups (Figure 5-4A), which suggested that the fibrin networks 
under the influence of IL-1β and t-PA were susceptible to break down compared to those in 
PBS alone. Consistent with this, after t-PA was added to the clots, there was a signiﬁcant 
increase of D-dimer detected at every time point (1, 4, 8, 18, and 24 h), compared to the PBS / 
blood clot group (spontaneous fibrinolysis). Already within 1 h after the addition of t-PA 
there was an increased amount of D-dimer detectable, implying that the thrombolytic activity 
had been initiated (Figure 5-4B). When IL-1β was added, there was a reduced rate of 
thrombolysis compared with IL-1β free controls (p < 0.05) (Figure 5-4B). In addition, we 
also recorded a 10 % weight loss due to spontaneous fibrinolysis in the PBS only group 
compared to the 500 pg/ml IL-1β treatment group (p < 0.01) (Figure 5-4C). 
 
5.4 Discussion 
When fracture occurs, extravasated blood from ruptured vessels quickly coagulates to 
produce a fracture hematoma as the first bridge between the broken bone fragments 
(Schmidt-Bleek et al., 2012). The hematoma provides little or no mechanical support and 
serves principally as a loose fibrin scaffold into which cells migrating from surrounding 
tissues (periosteum) can embed to exploit their angiogenic and osteogenic repertoire 
(Groothuis et al., 2010). This is a comparatively rapid process that yields a mechanically 
stable hematoma composed mainly of platelets and fibrin fibers (Furie et al., 2008). Parallel 
with the recruitment of platelets, enormous molecules, such as fibrinogen and 
proinflammatory cytokines, are released from the storage granules of activated platelets and 
further participate in the blood coagulation, thus modulating the clot structures (Allan et al., 
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2012; Morrell et al., 2014). Importantly, the simultaneous activation of coagulation reaction 
and inflammation have been shown to interact and engage in mutual crosstalk (Levi et al., 
2004). The structural properties of the fibrin matrices can influence cellular activity during 
the healing process (Gomez-Barrena, et al., 2015; Nurden, 2007) but, surprisingly, few 
studies have investigated the effect of inflammatory cytokines on the structural properties of 
blood clots. Although the effects of IL-1β on PPP clot structures have been reported in our 
previous experiments, body’s natural hemostasis in the clinical setting involves all blood 
components including blood cells that contribute to form a blood clot. In consideration of this 
concept, we selected the whole blood as the research objective in this study. 
In this study, we investigated the in vitro effects of IL-1β on fibrin polymerization and found 
that clots treated with 500 pg/mL IL-1β had shorter splint point, R, and K time, while the α 
angle and MA value were greater. These findings substantiated the hypothesis that a higher 
concentration of IL-1β speeds up coagulation, partly by facilitating the – cross-linking of 
fibrinogen between protofibrils (Sahni, et al., 2004). Using high magnification SEM, we 
observed a notable decrease of fiber thickness (approximately 51.4 %) and increased fiber 
density in the 500 pg/mL IL-1β group, which was strong evidence for the structure altering 
effects of IL-1β on blood clots. Compared to clots formed by purified fibrinogen solutions 
and PPP clots in the previous studies (Wang et al., 2016), the fiber thickness in the 500 
pg/mL IL-1β treatment groups was reduced by 56.9 % and 61.2 %, respectively, suggesting 
that the involvements of platelets and red blood cells could affect clot structure to some 
extent.  
These changes to the fibrin structure resulted in significant changes of the clots’ mechanical 
properties. The Young’s modulus of blood clots in the 500 pg/mL IL-1β treatment groups 
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was significantly higher compared to the control group and IL-1β treatment also resulted in a 
slower rate of thrombolysis. These results agreed with a 2010 study that reported decreased 
clot permeability resulting from inflammatory cytokines (Wolberg, 2010). Our experiments 
demonstrate for the first time a direct association between the proinflammatory cytokine IL-
1β and fibrin structure in human blood. IL-1β contains a β-barrel structural feature similar to 
fibroblast growth factor-2 (FGF-2). This β-barrel binds to the carboxyl terminus of the γ 
chain in fibrinogen, which is associated with fibrin polymerization, crosslinking, and platelet 
interaction (Sahni et al., 2003; Sahni, et al., 2004; Varadi et al., 1986). The presence of IL-1β 
may also enhance the procoagulation activity of platelets by increasing the level of thrombin, 
somehow yielding clots with thinner fibers (Leviton et al., 2004; Opal, 2000). Therefore, 
there was a greater reduction in fiber diameters in PPP clots (61.2 %), compared to 56.9 % in 
purified fibrin clots. Exactly how IL-1β interacts with target cells at the fracture site is still 
unclear and requires further investigations. 
A range of cytokines, such as proinflammatory mediators, are known to be important for 
hemostasis in early stages of fracture repair (Claes et al., 2012). However, the mechanisms 
that link proinflammatory cytokines, such as IL-1β and fiber structure is still unclear. The 
observations made in this study confirm the strong pro-coagulatory effects of IL-1 during 
thrombogenesis, which was in line with outcomes in PPP clots. These findings will aid in 
developing innovative approaches to modify hematoma structures, particularly the use of 
biological agents, which could assist in the regeneration of large segmental bone defects. 
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5.5 Conclusion 
IL-1β has a profound effect of clot kinetics and alters the structural and biomechanical 
properties, as well as thrombolytic activity, of human blood clots. The observations made in 
this study give us a better understanding of the procoagulatory functions of IL-1β and 
supports the hypothesis that structural changes of the blood clot have measurable effects on 
bone healing, which suggest a possible mechanism for the delayed rate of healing in large 
bone defects. 
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Chapter 6: Discussion 
Chapters 2 to 5 cover the principal contents of this thesis. This chapter recapitulates the most 
significant findings of the experiments and discusses how to develop a putative method to 
augment de novo bone regeneration in large defect sites by tailoring the fibrin clot meshwork.  
 
General discussion 
6.1 Principal findings 
Upon bone injury, hematoma formation is initiated by the rapid recruitment of circulating 
platelets where they exploit the function of hemostasis which includes thrombosis. 
Hemostasis is regarded as a dynamic event that requires the involvement of a number of 
interacting components, such as, platelets, clotting factors, platelet-related proteins, and 
inflammatory cytokines (Claes et al., 2012). As a result, the formation of glue-like fibrin net 
is thought to be the final step of proteolytic cascades, which can provide the mechanical 
framework for hematoma growths. In spite of the accepted significance of the fibrin 
meshwork, knowledge of its characteristic architecture is limited. Therefore, the anatomy and 
physiology of fracture hematomas and its potential to clinical implementation were 
systematically reviewed.  
According to the literature, we firstly recognized that the architecture of intravascular 
thrombus formed through the intrinsic pathway can be meticulously divided into two 
phenotypes: loosely-woven clot conformation with thicker fibers and tightly-packed clot 
conformation with thinner fibers (Collet et al., 2000). Most importantly, it has been reported 
that pathologic clot phenotypes (i.e. densely-packed and thinner fibers) causing a resistance 
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to fibrinolysis has a positive connection with many thrombotic disorders, such as, stroke and 
peripheral arterial diseases (Ariens, 2013; La Corte et al., 2011). During fibrin assemble, the 
clot structure abnormalities can be influenced by local conditions that contain, but are not 
restricted to, ionic strength, concentrations of fibrinogen, thrombin, and platelets (Wolberg et 
al., 2008). Based on the knowledge on thrombus, it is hypothesized that formation of fracture 
hematomas through the extrinsic pathway may also be further categorized. 
Current knowledge on the fracture hematoma has been acquired from analysis of its 
supernatant: low pH, high phosphate, alkaline phosphatase, and lactate values (Kolar et al., 
2010). In addition, in the sheep middle shaft defect osteotomy, it has been demonstrated that 
cellular composition in fracture hematoma at 1 h and 4 h contained a higher percentage of 
granulocytes and macrophages but less lymphocytes comparing with peripheral blood 
(Schmidt-Bleek et al., 2009). In an ovine 3-mm middle shaft osteotomy model, the majority 
of fracture hematoma evolved into granulation tissue within around 7 days and disappeared at 
14 days (Kolar, et al., 2010). In a mouse cortical bone defect model, hematoma 
mineralization was pronouncedly observed at day 9 and new bone modelling was evident at 
day 14 using histological analysis (Campbell et al., 2003). Despite the large body of research 
into the importance of hematoma formation in fracture healing, there is no report that 
describes the differences between the structural and biological properties of hematomas 
formed between normal-healing fractures, which normally heal by themselves, and large 
bone defects, which result in delayed healing process. It is noted that manipulating the gap 
sizes of bone defects has been well-studied to be a biological approach to achieve normal, 
delayed, and non-union model in animals (Pek et al., 2008). For example, a previous study 
has showed that 1-mm-diameter circular craniotomy defects had almost completely healed 
(92 %) within 14 days after surgery in rats (Santana et al., 2003), an indication that 1-mm-
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diameter defect healed rapidly through direct healing (intramembranous ossification) (Di et 
al., 2014). Therefore, 1-mm-diameter defects have routinely been used as normal healing 
models in rats (Hoerth et al., 2014; Mehta et al., 2012). Contrast this with Cao’s 2015 study 
which showed that even after 90 days the BV/TV in the 3-mm-diameter × 2-mm-depth 
defects in rats was only 76.5 % ± 3.0 %, suggesting the defects had not fully healed (Cao et 
al., 2010). According to the criteria for bone fracture healing (Mills et al., 2012), a fracture in 
rats can be expected to heal within 4 – 6 weeks (28 – 42 days) and they defined any bone 
defect in rats taking 42 days or more to heal as delayed healing. 
On the other hand, PRPs are similar to the hematoma and consists of blood plasma enriched 
with a high concentration of platelets and growth factors; these have been trialled in both 
animal and human (Gianakos et al., 2015; Giudice et al., 2016). PRPs are supposed to secrete 
a variety of growth factors and cytokines at supra-physiological concentrations, and generate 
a cell-supporting matrix in the form of a fibrin clot (Iqbal et al., 2011; Kurikchy et al., 2013). 
Nevertheless, the results from experimental (Simman et al., 2008) and clinical studies (Marx 
et al., 1998) using PRPs in oral and maxillofacial bone grafting procedures are controversial, 
and to date there is little evidence to suggest it actually improves or accelerates bone healing; 
in fact, in the majority of cases there was a decrease in bone formation (Choi et al., 2004; 
Marden et al., 1993). The factors accounting for the ambiguous outcomes have not been 
identified, but it has been suggested that a tight fibrin clot network was formed (Dohan 
Ehrenfest et al., 2009) during the manufacture process thereby probably obstructing cellular 
movement and reducing its experimental and clinical effectiveness. 
Based on the poor performance of PRPs, PRFs were introduced as “second generation” 
platelet concentrate by French researchers around the turn of the century (Choukroun et al., 
2006). It is described as a more natural fibrin matrix containing all the constituents of blood 
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that are favourable to healing and immunity and has specific advantages: the clotting process 
in PRFs takes place by a slower natural polymerization compared to a fast polymerization 
resulting when thrombin is added to PRPs, and it is simpler to obtain PRFs since autologous 
blood is drawn from the patient (Dohan et al., 2006). Studies have shown that PRFs, after 
implantation in the injury site, have a more sustained release of growth factors, such as PDGF, 
TGF, and BMPs, lasting up to 28 days (He et al., 2009; Liu et al., 2013). This release profile 
is significantly different to PRPs, which are characterized by a burst release of cytokines and 
growth factors within one day. Despite this, PRFs have not shown any significant 
improvements when applied in oral and maxillofacial surgery (Choukroun, et al., 2006), and 
as far as we can glean from the scientific literature, there are no studies that have investigated 
the effectiveness of PRFs in healing large defects of long bones. Even though some studies 
do suggest that PRF is a better product compared to its counterpart, PRP, the scientific 
studies are not convincing and require further investigation, specifically in relation to the 
repair and regeneration of long bones. 
In this project, we have conducted animal studies in rats in which 1 and 3 mm size defects 
were drilled in the distal femur. Using SEM we observed discernible structural differences 
between blood clots formed in the smaller (1 mm) compared the larger (3 mm) defects. For 
example, the clots from the 1 mm defects had a more porous structure and thicker fibrin 
fibers compared to the clots from the 3 mm defects. To further investigate the fibrin 
characteristics, SEM Quanta 200 at a magnification of 5000 × showed that the clots in the 3 
mm defects had thinner and tighter fibers in compared to the clots in the 1 mm defects in 
which the fibers were thicker and looser (P < 0.01). Furthermore, enzyme-linked 
immunosorbent assays were used to evaluate the concentration of the following inflammatory 
cytokines: IL-1β, IL-6, IL-10 and TNF-α; these are some of the key factors released from the 
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platelets during initiation of the repair process. Statistical analyses of these amounts of 
proteins showed that there was a higher level of IL-1β in the 3 mm defects (745.40 ± 99.19 
pg/mL) comparing to the 1 mm defects (57.46 ± 4.72 pg/mL), but no significant differences 
in IL-6, IL-10, and TNF-α have been found. Subsequently, the investigated effects of IL-1β 
on purified fibrinogen in vitro had been verified through a series of assays including turbidity 
measurements, SEM, CM, rigidity, and fibrinopeptide release study, indicating that the 
presence of IL-1β (500 pg/mL) can significantly reduce fibrin diameter and increase fibrin 
density. 
To further demonstrate that alteration of fibrin clot structure could influence the bone healing, 
GSNO, known as an antithrombotic agent, has been used to modulate hemostasis via 
suppressing platelet activation and aggregation (Radomski et al., 1992; Riba et al., 2004; 
Simon et al., 1993). Also, GSNO has been documented to directly bind to the αC domain of α 
chain in fibrinogen molecule, changing its secondary structure thus increasing fiber size 
(Akhter et al., 2002). In support of this, the effects of GSNO on fibrin polymerization kinetics 
in pure fibrinogen solution and human platelet poor plasma have been well reported 
(Bateman et al., 2012; Geer et al., 2008). In addition to affecting platelet and fibrinogen, 
GSNO has also been shown to hamper the enzymatic activity of coagulation factor XIII 
therefore reducing fibrin cross-linking both in vitro and in vivo (Catani et al., 1998). In 
animal model, intragingival injection of GSNO was demonstrated to be an effective 
therapeutic drug to attenuate inflmmation reaction and induce bone neoformation (Chow et 
al., 1998; de Menezes et al., 2012). Clinically, GSNO has been routinely employed to prevent 
myocardial infarction and restenosis (Langford et al., 1996; Sorragi Cde et al., 2011). 
Given that fiber diameter can be increased by the action of GSNO, local application of GSNO 
mixed with blood within delayed bone defects has been tested in rat model. Under the 
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observation of SEM, fiber thickness of blood clots founded within delayed healing defects 
reached to the peak values (596.6 ± 249.4 nm) at 1 mM GSNO, but fiber desity significantly 
decreased to 5.2 ± 2.3 / 4 µm2 compared to 18.0 ± 2.7 / 4 µm2 in the control group (P < 0.01). 
To further validate  the hypothesis that manipulation of fibrin structure can influence bone 
minerilization process, new minerilized bone tissues between the control group and GSNO 
treatment groups were evaluated using micro-CT. It was revealed that newly-formed bone 
volume in the 1 mM GSNO groups increased to 18.4 % ± 1.3 % and 63.7 % ± 14.1 % at day 
7 and 28 respectively compared to the control (P < 0.05), indicating that alterations of fibrin 
properties were closely associated with new bone formation. This finding was consistent with 
a previous study showing that thicker and well-aligned fibers can provide a more favorable 
fibrin template for guided bone tissue repair and reconstruction (Lyu et al., 2013). 
In addition to purified fibrinogen solution, rat PPP, the blood fraction with reduced platelets, 
were also investigated to verify the relationship between IL-1β and clot structures. Our study 
reported the positive impacts of IL-1β (500 pg/mL) on fibrin polymerization in PPP clots 
using turbidity measurements. While evaluating the effects of IL-1β on clot architecture using 
SEM, we found significantly decreased fiber diameters and pore sizes with increased 
concentrations of IL-1β. These findings were in line with confocal microscopy images 
revealing that 500 pg/mL IL-1β was responsible for the formation of significantly 
impermeable PPP clots. The release rates of D-dimer were dynamically detected in the 
fibrinolytic assay over 24 h, which reflected formation of compact clots in the presence of IL-
1β (500 pg/mL). The compact structures of PPP clots were closely correlated with prolonged 
weight loss and lysis time, indicating that proteolytic enzymes such as t-PA were inaccessible 
to invade the tight fibrin network. Therefore, our findings suggested that PPP clots with 
denser fibers are resistant to lysis and that this may be attributed to the high concentrations of 
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IL-1β (500 pg/mL). This may explain the findings in a previous study by Sjoland et al. who 
demonstrated that abnormal fibrin clots with low permeability and lysability occurred under 
the condition of inflammatory disorders (Sjoland et al., 2007). 
Finally, we also showed that IL-1β (500 pg/mL) contributed considerably to human blood 
clot structure, which is closer to real situation at bone defect sites. We traced altered 
thromboelastographic curves under the assistance of thromboelastography suggesting the 
impact of IL-1β on the reduced clotting time and decreased maximal fiber turbidity. The 
structural data including fiber diameter and density were quantitatively analysed under SEM, 
and these findings were consistent with another study that showed that the presence of 
proinflammatory cytokines could significantly decrease the clot porosity (van Rooy et al., 
2015). The compression assay evaluation revealed formation of stiffer clots resulting from 
IL-1β (500 pg/mL), whereas there was no statistically difference between 50 pg/mL IL-1β 
and the control group. This outcome was corroborated by a study showing the fibrin 
meshwork made up of thinner and highly branched fibrin strands performed a more rigid 
mechanical property (Undas et al., 2011).  
Moreover, thrombolytic assays of human whole blood samples demonstrated varying clot 
properties with different lysis phenotypes due to IL-1β administration. Indeed, the fibrin clot 
network composed of dense thinner fibers has been shown to be more resistant to lysis than 
those made up of looser and thicker fibers (Collet et al., 2004). Additionally, the profound 
inhibitory effect of IL-1β on the fibrinolytic activity in human endothelium has been linked to 
a reduction of t-PA secretion and up-regulation of PAI expression that impairs fibrinolysis 
(Warocquier-Clerout et al., 1991). Similarly, other proinflammatory cytokines such as TNF-α 
have been shown to have a positive correlation with higher levels of PAI in patients with 
infectious pleural effusions (Aleman et al., 2003). As a result, a recent study has been shown 
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that prolonged fibrinolysis due to plasmin deficiency can be considered a main culprit behind 
delayed bone healing or non-union (Yuasa et al., 2015). 
The series of experiments completed in this thesis, for the first time, unveiled that the 
structural properties of hematomas formed at different sizes of bone defects have been 
classified into two divisions: loosely-woven fibrin framework in smaller bone defects and 
tightly-arranged fibrin framework in larger bone defects. It is also demonstrated that 
anticoagulation medication, such as GSNO, was attempted to alter an in situ hematoma 
meshwork (fiber diameter and density) that can undergo timely fibrinolysis mediated by 
plasmin. This proof-of-concept study could develop a potential therapeutic approach to 
accelerate bone regeneration in large bone defects. 
 
6.2 Potential mechanisms 
Generally, hemostasis is achieved at a fracture site by the concurrent release of pro-
inflammatory cytokines and clotting factors from plasma, thereby initiating the coagulation 
cascade. There are three main pathways whereby inflammatory mediators participate in the 
clotting process: by propagating coagulation, impairing anti-coagulation, or inhibiting 
fibrinolysis (Demetz et al., 2012; Leviton et al., 2004; Lipinski et al., 2011). Similarly, fibrin 
fibers as the principal coagulation product can amplify inflammatory response by the release 
of a number of elements from activated platelets and stimulated blood cells, thus improving 
cell-cell interactions that perpetuate the inflammatory state (Esmon, 2005). The tight linkage 
of inflammation and coagulation has been explored in previous studies (D’Angelo, 2015; 
Szaba et al., 2002).  
However, mechanisms by which IL-1β is associated with altered fibrin clot constructs remain 
unclear. Binding of IL-1β to the carboxyl terminal region of gamma chain in fibrinogen has 
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been documented, but the exact interactive sites are still poorly characterized (Sahni et al., 
2004). It is likely that IL-1β affecting fibrinogen functional sites might explain differences in 
fibrin clot properties, since this carboxyl terminal region involves in fibrin polymerization 
(Varadi et al., 1986), crosslinking (Chen et al., 1971), and platelet interaction (Kloczewiak et 
al., 1984; Lam et al., 1987). On the other hand, the stimulation of proinflammatory cytokines 
to endothelial cells can produce excessive tissue factors, yielding a highly dense fibrin clot 
(Wolberg, 2010). Notably, the fibrin network became tighter when the physical distance from 
the cell surface was closer, implying that there was an effect of “surface-related” factors on 
clot architecture (Campbell et al., 2008). 
Another contribution of pro-inﬂammatory cytokines is to enhance the procoagulant activity 
of platelets (Gorbet et al., 2004; Kaser et al., 2001). Importantly, platelet activation is thought 
to be the major player in the properties of fibrin clot, partly due to its retraction force (van 
Rooy, et al., 2015). Inflammation-mediated platelets can generate a loop that prolongs the 
inflammatory state in two aspects. Firstly, accumulation of activated platelets results in the 
phospholipid surfaces acquiring negative charge, thereby inducing the occurrence of 
secondary hemostasis. The resultant product, termed as “Protease Activated Receptor (PAR)”, 
has been identified as a potent inflammatory mediator (Esmon et al., 1999). Secondly, 
platelet-induced alterations in endothelial cells have been tested in association with IL-1β, 
and stimulated endothelial cells are able to release a large amount of pro-inflammatory 
cytokines (Gawaz et al., 2000). 
 
6.3 Limitations 
These are naturally limitations to this thesis. Firstly, in addition to fiber thickness and density, 
other fibrin characteristics, such as clot porosity, permeability, and branching points, are still 
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critical for the biological behaviour of BMSCs thereby influencing normal bone 
mineralization process. Thus, there is a need for investigations that target the structural 
properties of fibrin clots in early hematomas. 
Secondly, fibrin differences in hematomas found within normal bone healing defects and 
delayed bone healing defects could be partly attributed to high levels of IL-1β proteins in this 
project. However, the coagulation cascade consists of multiple chemical reactions and 
substantial factors, such as fibrinogen, thrombin, IL-6, IL-10, thrombospondin, and 
polyphosphate must also be taken into account for explaining the clot differences. 
Thirdly, this project only compared the fibrin features in hematomas from spontaneous bone 
healing and delayed bone healing animal models, rather than those from the critical-sized 
defects that represents of more genuine non-healing models. 
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7.1 Summary of the Thesis 
The leakage of blood plasma from injured bone defects leads to the sequential initiation of 
coagulation enzymatic cascade that terminates in the growth of a hemostatic blood clot 
(Dimitriou et al., 2005). Owing to the existence of necrotic materials, inﬂammatory response 
associated with the release of pro-inﬂammatory cytokines from degranulated platelets, such 
as IL-1, IL-6, and TNF-α, is thought to have chemotactic activity to recruitment of BMSCs, 
endothelial cells, and lymphocytes toward the hematomas (Kon et al., 2001). The efficient 
and timely clearance of hematoma is crucial to provide sufficient space for cellular ingress 
and tissue reorganization, and impaired fibrinolysis has been postulated a major cause of 
delayed healing or non-healing (Yuasa et al., 2015). Despite this, during the initial phase of a 
bone fracture the protection of the hematoma (i.e. fibrin matrix) is still emphasized in the 
therapeutic protocols of fracture-healing (Koga et al., 2013). 
In Chapter 2, in which we reviewed the existing literature on fracture hematomas, it was 
apparent that the structure and potential of a fracture hematoma are essential factors in early 
bone tissue regeneration. Consequently, we attached greater importance to the process of 
fibrin polymerization in this review prior to the commencement of this project. Based on our 
reading of the scientific literature on hematomas, investigations on the structural properties of 
normal bone healing and delayed bone healing did not appear to have been conducted 
previously. We therefore proposed that the structural and biological properties of hematomas 
formed during normal and delayed healing should exhibit qualitative and quantitative 
differences and result in different healing outcomes. Clarifying the structural properties of 
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normal hematomas would provide an innovative foundation to develop novel treatment 
strategies to bone healing. 
Secondly, we characterized the structural properties of hematomas from normal bone healing 
defects and delayed bone healing defects. We found small pores that were apparent in the 
early fibrin network (Day 1) at the edges in the 1 mm defects, whereas a highly tight fibrin 
framework (Day 1) at the same position was seen in the 3 mm defects. At day 4, the 
transformation of hematomas into fibrous tissues could be seen in the 1 mm defects but not in 
the 3 mm defects. High magnification SEM was used to assess fiber diameter and density, 
and the difference in the bone healing was clearly evident by this method of observation 
(Figure 7-1). In samples with loosely-woven fibers harvested from the smaller defects, the 
healing was normal, whereas in hematomas with densely-packed fibers, harvested from the 
larger defects, the healing was delayed. Gene expressions of inflammatory cytokines were 
assessed by quantitative PCR, and protein concentrations were measured by ELISA kits. 
These assays showed significantly higher levels of IL-1β in the 3 mm defects compared to the 
1 mm defects. 
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Figure 7-1: The relation between hematoma phenotypes and bone healing. 
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During hemostasis, a number of variables, such as pH value, ionic strength, concentrations of fibrinogen, 
thrombin, and calcium, can exert a significant impact on fiber formation by interacting α-, β-, or γ- chains of 
fibrinogen. As a result, two different phenotypes of hematomas were formed: loosely-woven and porous fibrin 
structure is composed of thicker fibers, while densely-packer and impermeable fibrin structure consists of 
thinner fibers. The porous fibrin structure (optimal) provides a favourable framework for supporting cellular 
infiltration from surrounding tissues and maintaining the continuous release of growth factors from the fibrin 
matrix, as well as is timely degraded by plasmin that is a proteolytic enzyme. These events will facilitate to 
development of fresh granulation tissues in a normal course and vice versa. 
 
Thirdly, we sought to determine in vitro whether IL-1β had an impact on fibrin structure 
using methods such as turbidity measurements, thromboelastography, SEM, CM, 
biomechanical study, compaction, and fibrinolytic / thrombolytic assay in purified fibrinogen 
/ rat platelet-poor plasma / human whole blood. Quantitative evaluations of a fibrin clot’s 
susceptibility to lysis revealed significant differences in the 500 pg/mL IL-1β groups 
compared to the controls. Together, these data demonstrated that a tightly-packed and rigid 
clot with thinner fibers was more resistant to lysis and was strongly associated with the 
addition of high concentrations of IL-1β. 
Finally, SEM analysis of the structural properties of an in situ bone defect hematoma altered 
using GSNO revealed increased fiber diameter of the hematomas and correlated strongly with 
enhanced and accelerated healing in the large defect model. Radiographic data from µCT 
revealed that the rate of new mineralized bone tissues were significantly faster in the 1 mM 
GSNO treatment groups compared with controls. This study is the first of its kind to explore 
the use of GSNO to experimentally alter the structural properties of hematomas in order to 
enhance the healing of delayed bone defect in an animal model. 
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7.2 Future directions 
This study has raised a number of questions, still unanswered, regarding the exact molecular 
mechanism between IL-1β and GSNO on fibrin clot properties. Further studies are required 
to clarify the underlying relationships. Thus, we propose that investigations be conducted to 
identify the dynamic interactions between GSNO and IL-1β on fiber characteristics using 
circular dichroism spectropolarimetry. Moreover, assays on the stimulatory effects of IL-1β 
on platelets and/or other blood cells be conducted to determine whether the kinetics of 
thrombin generation using antibody-antigen technology. Furthermore, the conformational 
changes of the fibrin clots in relation to bone defect healing should also be examined.   
Fibrin is produced by the final step of the coagulation cascade and the fibrin clot is in effect a 
natural biopolymer scaffold that provides a template for continuous tissue regeneration. The 
fibrin architecture can be altered by varying fibrinogen or thrombin concentrations, and the 
rate of fibrinolysis can be determined by plasmin concentration (Mosesson, 2005; Wolberg, 
2007). It is now increasingly recognized that clots formed by low concentrations of thrombin 
have a more porous 3-D structure that is more favourable for tissue repair (Breen et al., 2009). 
Fibrin has the obvious benefits of being fully biodegradable and does not elicit an 
inflammatory reaction or foreign body fibrotic encapsulation. The latter is to a large part 
responsible for the failure of synthetic implants to integrate with adjacent bone (Jackson, 
2001), whereas artificial fibrin products such as fibrin sealants and hydrogels have been 
widely used as a hemostatic device and for drug delivery in surgical applications.  
There is now ample evidence to support the use of fibrin sealants as reliable implant material 
that assists bone healing (Cunha et al., 2015; Iatecola et al., 2013; Kania et al., 1998). A fibrin 
hydrogel can provide porous structure that is amenable to cellular activities that can increase 
cell proliferation rates (Bootle-Wilbraham et al., 2001; Kirilak et al., 2006). In addition, a 
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fibrin hydrogel acts as a delivery vehicle for a sustained release of growth factors to the target 
area of bone tissue regeneration without affecting their bioactivities, thus diminishing the 
potential risks accompanied by systematic administration (Fowlkes et al., 2006).  
In contrast to commercial fibrin products, our findings have demonstrated a new paradigm to 
enhance de novo bone regeneration by manipulating in-situ fibrin structure in hematomas 
during the healing process. Prospectively, more thorough characterization of the initial 
fracture hematoma is needed to be able to have a ‘gold standard’ for future fabrication of 
autologous fibrin-based scaffold capable of significantly accelerating regeneration of large 
bone defects. 
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